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Abstract
Ion beam therapy is a rapidly developing branch of tumor treatment. Since ions deposit most
of the energy at the end of their ranges, they are good candidates for an effective treatment
of deeply-seated tumors together with an efficient sparing of the normal tissue in the beam
entrance channel. Currently, only protons and carbon ions are used in clinics. This work aims
at experimental study of the relevant properties and exploring the possibility of introducing
another ion type, 16O oxygen, to clinical practice, primarily for treatment of hypoxic tumors.
In this work, the first multi-scale description of 16O beams, including their experimental char-
acterization from the physical and radiobiological points of view, and the following treatment
planning studies, is introduced. Apart from that, the new approach suggesting the irradiation of
hypoxic tumors with several primary ions, implemented to the GSI in-house treatment planning
system TRiP98, is described and the corresponding treatment planning study is carried out with
oxygen and helium beams.
The verification of the absorbed dose profiles, as well as the in vitro cell survival experiments,
including the measurements in hypoxia, were carried out at the Heidelberg Ion-Beam Therapy
Center and GSI Helmholtz Centre for Heavy Ion Research (Germany). These experiments con-
firmed the present status of the physical and radiobiological beam models for oxygen beams
and the reliability of the produced treatment plans. For the first time, the benefit of oxygen ions
over carbon ions for irradiation of hypoxic tumors was experimentally indicated. The further
comparative study of the treatment plans with oxygen and lighter ion beams revealed that the
usage of oxygen ions for hypoxic tumors allows the most uniform target coverage, decrease of
the dose received by residual tissue in the entrance channel and avoiding local dose hotspots
in the organs at risk. Treatment planning studies using the kill-painting approach suggested
that by combining heavy and light primary beams within the same treatment plan one can fur-
ther improve the outcome of radiotherapy for some cases of hypoxic tumors due to the further
reduction of dose received by the critical structures and residual tissue.
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Zusammenfassung
Die Ionenstrahltherapie ist ein sich rasch entwickelnder Zweig der Tumorbehandlung. Da Ionen
den größten Teil der Energie am Ende ihrer Reichweite deponieren, sind sie gute Kandidaten
für eine effektive Behandlung von tief sitzenden Tumoren und ermöglichen gleichzeitig eine
effiziente Schonung des Normalegewebes im Strahleingangskanal. Derzeit werden nur Proto-
nen und Kohlenstoff-Ionen in Kliniken verwendet. Ziel dieser Arbeit war eine experimentelle
Untersuchung der relevanten Eigenschaften und eine Analyse der Möglichkeit, einen anderen
Ionentyp, 16O Sauerstoff, hauptsächlich zur Behandlung von hypoxischen Tumoren, in die klin-
ische Praxis einzuführen.
In dieser Arbeit werden die erste umfassende Beschreibung von 16O-Ionen einschließlich ihrer
experimentellen Charakterisierung sowohl aus physikalischer als auch aus strahlenbiologischer
Sicht sowie die daraus folgenden Studien zur Behandlungsplanung vorgestellt. Darüber hinaus
wird ein neuer Ansatz zur Bestrahlung von hypoxischen Tumoren mit mehreren Primärionen
beschrieben, der in das hauseigene Bestrahlungsplanungssystem TRiP98 von GSI implemen-
tiert wurde. Die entsprechende Behandlungsplanung wird mit Sauerstoff- und Heliumstrahlen
durchgeführt.
Die Verifizierung der Energiedosisprofile sowie die in vitro Zellüberlebensexperimente ein-
schließlich der Messungen in Hypoxie wurden am Heidelberger Ionenstrahl-Therapiezentrum
und am GSI Helmholtz-Zentrum für Schwerionenforschung (Deutschland) durchgeführt. Diese
Experimente bestätigten den aktuellen Stand der physikalischen und strahlenbiologischen Mod-
elle für Sauerstoff-Ionen und die Zuverlässigkeit der erstellten Bestrahlungspläne. Zum ersten
Mal konnte experimentell gezeigt werden, dass Sauerstoff-Ionen gegenüber Kohlenstoff-Ionen
für die Bestrahlung von hypoxischen Tumoren von Vorteil sein können. Der weitere Vergleich
der Bestrahlungspläne mit Sauerstoff- und leichteren Ionenstrahlen ergab, dass die Verwen-
dung von Sauerstoff-Ionen für hypoxische Tumore eine möglichst gleichmäßige Zielerfassung,
eine Verringerung der Dosis im Eingangskanal und eine Vermeidung lokaler Dosis-Hotspots in
kritischen Organen ermöglicht. Der hier vorgeschlagene Ansatz, der kill-painting mit der Ver-
wendung von mehreren Ionentypen mit verschiedenen Eigenschaften in einem Bestrahlungs-
plan verbindet, kann den Therapieerfolg für einige Fälle von hypoxischen Tumoren verbessern,
da eine zusätzliche Verringerung der Dosis im Normalgewebe und in kritischen Organen erreicht
werden kann.
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Introduction
First proposed in the 1970s in Berkeley [Tobias et al., 1971], cancer therapy with heavy ions
has recommended itself as a promising alternative to the therapy with photons and protons.
In contrast to the first type of irradiation, due to the ’inverse’ depth-dose profile, ions achieve
the same level of conformity for the tumor irradiation, while sparing the residual tissue more
efficiently [Schardt et al., 2010; Loeffler and Durante, 2013]. At the same time, compared to
protons, heavier ions offer reduced lateral scattering and higher radiobiological effectiveness,
thus leading to enhanced cell kill in the Bragg peak region [Durante and Loeffler, 2009]. The
branch of tumor treatment with particles is rapidly growing, and, by the end of 2015, about
150 000 patients received the corresponding treatment [Jermann, 2016]. Apart from protons,
at the moment the facilities in operation offer the treatment only with carbon ions, while some
of them are in principle able to deliver other particles. However, in the past decade the interest
towards introducing other modalities to the clinical practice has increased.
In particular, 16O oxygen beams are being widely discussed mainly due to their increased
linear energy transfer (LET). The main benefit one can get from this feature is the possibility to
overcome the problem of increased radiosensitivity of hypoxic tumors [Baverstock and Burns,
1976; Michael, 1996] due to the decreased values of oxygen enhancement ratio. The semi-
empirical models, describing the OER-LET dependencies based on the available experimental
data [Wenzl and Wilkens, 2011; Stewart et al., 2011; Scifoni et al., 2013; Antonovic, 2014;
Bopp et al., 2016] predict the drastic reduction of OER when the particle LET exceeds the value
of ≈100 keV/µm. The first trials with high-LET particles, mainly with neon 20Ne, were carried
out at Berkeley times [Tobias et al., 1982; Castro, 1995], however, at that time there was no
sufficient knowledge about the beam radiobiological properties. Researchers came back to the
idea of using heavier ions when the ideas of LET redistribution in the treatment plan were
proposed by the different groups (the so-called ’LET-painting’ [Bassler et al., 2010, 2014] or
’kill-painting’ [Scifoni et al., 2013; Tinganelli et al., 2015] approaches).
At the same time, the use of 16O ions possesses several drawbacks that need to be taken
into account, such as an increased dose behind the Bragg peak and in the entrance channel,
caused by the increased portion of nuclear fragmentation. Additionally, the increased relative
biological effectiveness (RBE) compared to the lighter ions, may also lead to an unnecessary
damage to residual tissue. Thus, the successful treatment of tumors with 16O beams requires
the precise knowledge about its physical and radiobiological properties, as well as complemen-
tary comparative treatment planning studies to identify in which cases they can be the most
beneficial.
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While already a few modern facilities offer 16O beams at a high level of dosimetric accuracy,
the full description of the beam is still missing. [Kurz et al., 2012] were the first to report
the results of experimental verification of physical depth dose distributions of oxygen ions at
Heidelberg Ion Beam Radiotherapy Centre (HIT). Further studies of 16O beams properties are
continued in the works of [Dokic et al., 2016; Tessonnier et al., 2017a,b], aimed at compar-
ing them with the lighter modalities, such as 12C, 4He, and protons, from physical and also
radiobiological points of view.
Despite the few treatment planning systems (TPS) starting to be able to handle 16O beam
model for planning [Tessonnier et al., 2017a; Inaniwa et al., 2017; Resch et al., 2017], the GSI
in-house TPS TRiP98 is the only TPS that is able to perform the optimization accounting for
the biological properties of the beam and tumor oxygenation. The latter is possible thanks to
the newly introduced "kill-painting" approach [Tinganelli et al., 2015] which by the start of the
current project was tested only with carbon ions.
In parallel to the idea of developing the tumor therapy with alternative ions, the interest
in combining several ions inside a single therapy session is rising. This way, the flexibility of
treatment planning is expected to be increased due to considering and optimally combining the
physical and the radiobiological properties of all the relevant ions, thus also avoiding the nega-
tive consequences caused by one ion by replacing it with another one if needed. Moreover, this
idea can be technically possible due to the recently reported short switching times between the
different ion species [Toshiba, 2017]. The first indications of the benefits of such an approach
were the use of a boost radiation during the treatment of patients. During the GSI pilot project,
this was a carbon boost for a smaller region of the tumor, after the primary irradiation with
photon fields. The later study presented by [Schulz-Ertner et al., 2005] demonstrated almost a
three-fold increase of the locoregional control after four years for the patients with ACC treated
in 1995-2003, who received a carbon boost in addition to the photon therapy, compared to
those who received the photon treatment only.
The study of [Böhlen et al., 2013] was already proposing the idea of achieving the constant
RBE inside the target by combining protons and carbon ions inside one treatment plan by op-
timizing with a constraint of a minimum variation of RBE through all the target. However, the
price to pay was the increase of the cell kill in the entrance channel. Another approach intro-
duced in the same work was the delivering of a heavy-ion boost to hypoxic regions of the target
to achieve a constant biological dose distribution. The latter idea arose from the previously
published works on dose- and LET-painting methods, introducing the ideas of redistributing the
particles LET during the treatment planning [Bassler et al., 2010; Brahme, 2011; Bassler et al.,
2014; Unkelbach et al., 2016]. The recent paper of [Inaniwa et al., 2017] demonstrated the
first implementation of the intensity modulated composite particle therapy (IMPACT), which
enables the optimization of the dose and the LET distributions in a patient. At this point, no
radiobiological models were included in the planning, and the optimization was carried out only
for the absorbed dose and a given LET.
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Nowadays the only TPS which can perform the simultaneous biological optimization of several
different ion fields is TRiP98. [Krämer et al., 2014] demonstrated a proof-of-concept example of
such optimization with 12C and protons for a C-shaped target representing the tumor wrapping
an OAR. However, up to now, there was no tool available, which can simultaneously perform
the optimization of several ion fields, accounting at the same time for the tissue radiosensitivity
and tumor hypoxia.
The presented work was pursuing two goals:
• Further characterization of 16O ion beams aimed at their future implementation in clinics.
For that, its relevant physical and radiobiological properties were studied and verified
experimentally, and extensive treatment planning tests with 16O beams were carried out.
• Enabling the optimization with several primary ions accounting for tumor hypoxia by ex-
panding the current version of TRiP98 TPS, and testing its validity with 16O beams.
The structure of this dissertation is as follows. Chapter 1 gives an overview of the current
status of ion beam therapy and the related physical aspects. In Chapter 2 the results of experi-
mental verification of oxygen beam properties, relevant for their clinical application in radiation
therapy are reported. This implies the absorbed dose profiles verification, as well as the radio-
biological measurements in normoxia and hypoxia. In Chapter 3 the results of the comparative
treatment planning tests with oxygen beams are presented for normoxic and hypoxic targets.
The idea of further improvement of the treatment of hypoxic tumors with oxygen beams by
combining them with the lighter modalities inside one treatment plan is proposed and tested in
Chapter 5. The work is rounded up with a conclusion which summarizes the main results and
discusses the necessary future steps.
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1 Research background and fundamentals
1.1 Ion beam therapy
The principal goal of cancer therapy is to eliminate all the cancer stem cells in a primary
tumor and regional lymph nodes while avoiding the damage to the residual tissue as much as
possible [Baumann et al., 2016]. Nowadays radiotherapy is one of the essential components of
cancer therapy along with surgery and chemotherapy, and quite often these methods are used
in combination.
About 80% of the people receiving the radiotherapy are getting treatment with X-rays, the
rest is treated with the brachytherapy or gamma-knife; the ion beam therapy with protons or
heavier ions is only 0.8% [Durante and Paganetti, 2016]. However, the number of patients, who
received this treatment, is increasing every year.
The pioneering work was conducted at Lawrence Berkley Laboratory (USA) where 2487 pa-
tients were treated in 1957-1992 [Castro, 1995; Castro et al., 1994]. The treatment was carried
out with 4He helium beams and heavier modalities such as neon 20Ne, with which 440 pa-
tients were treated. Apart from that, few patients were exposed to 18Ar and 14Si, however,
these trials had to be terminated because of the severe side effects since at that time no proper
radiobiological model for heavy existed.
Currently, the ion beam therapy is performed only with protons and 12C ions. Since the
Berkeley times, the related physical and radiobiological knowledge have significantly improved.
However, there are still many challenges remaining. Among them are the intrafractional mov-
ing of several tumor types such as lung cancer, the problem of describing the radiobiological
response of the tissue using the particles’ RBE, tumor hypoxia, etc. Despite that, the number of
patients is rapidly growing. According to [Jermann, 2011, 2016], in the last five years, the total
number of patients treated with ions had increased almost twice from 84492 to 154203. Re-
garding the operating facilities, currently, there are in total 11 12C centers, situated in Germany
(2), Japan (5), China (2), Italy (1) and Austria (1). Regarding the proton therapy centers, the
geographical distribution is much broader, and there are 64 facilities in 17 countries [PTCOG,
2016a]. Figure 1.1 summarizes the PTCOG most recent data. Apart from that, at the time of
this writing there are 41 facilities in the building stage [PTCOG, 2016b].
While only the two ion types are actually being used, there is a high interest in implementing
the alternative modalities, such as 4He or 16O. The first one is mainly discussed as an alternative
to protons (a so-called "better proton") and the plans on the start of the clinical trials in the next
years are being reported [Haberer et al., 2017]. The physical and radiobiological evidence for
using these ions will be addressed in the following sections in this chapter.
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Figure 1.1.: Geographical distribution of the operating proton and carbon ion radiotherapy cen-
ters. The numbers in circles represent the number of corresponding centers in the
country. Based on the statistics provided by PTCOG [PTCOG, 2016a].
1.1.1 Basic physics of ion beam therapy
The main argument for using ions in radiotherapy is their inverse depth-dose profile, often
referred as a Bragg curve [Bragg and Kleeman, 1905]. In contrast to the X-ray radiation, demon-
strating the steep energy decrease in depth, or a broad peak near the surface of the patient’s
body, the depth-dose distribution for protons or heavy ions has a pronounced narrow maximum
at the end of the range while delivering a relatively low dose in the entrance channel.
In radiotherapy, the absorbed dose is measured in Gray [Gy] and is defined as the energy dE
absorbed in a mass element dm:
D =
dE
dm

1Gy= 1
J
kg

. (1.1)
The dose delivered in a thin layer of material by the parallel beam with particle fluence F can
be calculated as follows:
D[G y] = 1.6× 10−9 × dE
dx

keV
µm

× F[cm−2]× 1
ρ

cm3
g

, (1.2)
with dE/dx standing for the energy loss per unit path length (’stopping power’) and ρ for the
density of the material.
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The main physical process contributing to the longitudinal profile of the ion beams is the ion-
ization of the atomic shell electrons. The lateral profile, characterizing the beam broadening, is
mainly affected by the elastic scattering on the target nuclei. Another essential process affecting
both the longitudinal and lateral profiles of the beam is the nuclear fragmentation.
Electromagnetic energy loss
The total stopping power for the ion is the sum of those for the electromagnetic energy loss,
due to interactions with the nuclei and due to radiative energy losses. The latter two, however,
are not relevant for the ions of therapeutic energies.
The electromagnetic energy loss rate dE/dx of the ion due to the inelastic collisions with the
electrons of the target is described by the Bethe-Bloch formula [Bethe, 1930; Bloch, 1933; Fano,
1963]:
dE
dx
=
4pie4ZtZ
2
i
mev 2

ln
2mev
2
I
− ln  1− β2− β2 − C
Zt
− δ
2

, (1.3)
where Zt and Zi stand for the nuclear charges of the target and the ion, e and me are the electron
charge and rest mass, v - the velocity of the ion, and β = v/c, where c is the speed of light in
vacuum. The last two terms are the shell (corrects for atomic bindings in the material) and the
density (for medium polarisation at high particle speeds) effects corrections, accordingly. The
ionization energy of the target atom or molecule, I , for protons and ions in water is ≈78 eV
[Schardt, 2007].
From the 1/v 2 terms it follows, that the energy loss is increasing with decreasing energy of
the particle. The peak region in the depth-dose distribution, where the energy loss of the ion
reaches its maximum is called Bragg peak.
In the continuous slowing down approximation (CSDA), when the energy loss is assumed
constant for every penetration depth, and the trajectory of the particle with initial energy E0 to
be a straight line, based on the equation 1.3 the range can be calculated as
RCSDA =
∫ E0
0
dE
dE / dx
. (1.4)
The statistical fluctuations of the energy loss lead to the broadening of the beam. The corre-
sponding energy loss fluctuations [Vavilov, 1957] for the multiple collisions on a first approxi-
mation can be described by the Gaussian distribution and result in a range straggling. The ratio
between the range straggling and the mean range remain nearly constant and is proportional to
1/
p
M where M stands for the particle mass. Thus, range straggling plays a less important role
for the heavier particles, resulting in a narrower shape of the Bragg peak.
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Lateral beam spread
The knowledge about the lateral scattering of the beam is essential for the estimation of the
doses received by the organs at risk (OAR) [Kraft, 2000]. The spread of the lateral profile of
the ions is caused by the elastic multiple Coulomb interactions with target nuclei. A commonly
accepted theoretical description for this effect was given by [Moliére, 1948] and confirmed by
the experiments with proton beams [Gottschalk et al., 1993]. The [Highland, 1975] approxi-
mation yields the following parametric equation for the characteristic multiple-scattering angle
θ [rad]:
σθ =
14.1 MeV
βpc
Zp
√√ L
Lrad

1 + 0.038 ln

L
Lrad

(1.5)
where β c, p, and Zp are the velocity, momentum and nuclear charge of the projectile, respec-
tively. L and Lrad characterize the thickness and the radiation length of the absorber. From the
equation 1.5 the three conclusions can be made:
• The targets containing heavy elements cause increased scattering of the beam, compared
to to the light-element targets of equal thickness;
• Due to the 1/(βpc) factor, the scattering decreases at higher energies;
• Heavier ions demonstrate a smaller lateral spread as compared to lighter beams at the
same range.
Figure 1.2.: Beam spread of the initially parallel narrow proton and 12C ion beams in a typical
treatment beam line. Figure taken from [Schardt et al., 2010].
Figure 1.2 demonstrates the lateral beam spread of protons and carbon ions in a typical
beamline. The beam exits from a nozzle, passes the 1 m air gap and enters a water absorber.
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12C exhibit a significantly lower scattering and the final beam width for the given energies do
not increase more than a factor of ≈1.5, while the scattering for protons is more significant.
Fragmentation
The knowledge of the fragmentation processes is essential for predicting the physical and
radiobiological effect of the ion beams, especially for the heavier modalities. The study of [Lühr
et al., 2012] has demonstrated the possible change of up to 10% in the prediction of the physical
dose in the SOBP region due to the 20% uncertainties in inelastic nuclear cross sections.
In the particle therapy with 12C ions only half of the primary ions reaches the Bragg peak
while the rest undergoes fragmentation [Durante and Paganetti, 2016], which leads to the fur-
ther lateral spread of the beam and the increased dose behind the Bragg peak, the so-called
fragmentation tail. The TRiP98 treatment planning system prediction of the fragment spectra
of the 160 MeV/u 16O ion beam slowing down in water is shown in Figure 1.3. As can be seen,
when the primary beam is lost at z ≈ 45 mm depth, the remaining fragments, which are mainly
protons and 4He, travel more than twice this distance.
Figure 1.3.: Buildup of secondary fragments produced by 160 MeV/u 16O beam slowing down in
water, generated by the TRiP98 software (described below). The plot of the right is
a zoom-in demonstrating the buildup of the heavier fragments.
The most commonly used model to describe the fragmentation process is abrasion-ablation (or
cascade and evaporation) model [Serber, 1947; Hüfner et al., 1975], illustrated in Figure 1.4.
At the abrasion stage, the nucleons in the projectiles overlap zone are sheared off forming the
’fireball’, and the peripheral nucleons remain almost not affected. The velocity of the produced
fragment is similar to the initial velocity and same refers to the ratio of mass over nuclear
charge (A/Z) f ≈ (A/Z)p. At the second stage (ablation) the remaining fragments de-excite
by thermalizing or producing neutrons, protons and lighter nuclei until reaching their ground
state. This step is described by a statistical model, with the probability of a fragment creation
depending on the energy on the excitation energy gained in the previous stage. The produced
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secondary fragments have the velocities very similar to the one of the primary projectile, and
their ranges are generally longer.
Figure 1.4.: Illustration of the abrasion-ablation model for nucleus-nucleus interactions at high
energies. Vp and Vf stand for the velocities of the initial particle and its fragment,
respectively.
The total reaction cross-section, describing the probability of all the possible nuclear reactions
in the interaction of the projectile with the target via nuclear forces, and including the charge-
changing and non-charge changing cross-sections, is the difference between the total and elastic
cross-sections. It can be described by the Bradt-Peters formula [Bradt and Peters, 1950]:
σr = pir
2
0

A1/3P + A
1/3
T −δ
2
(1.6)
with AP and AT standing for the masses of the projectile and the target, r0 = 1.1 fm for the
effective nuclear radius, and δ being the correction (overlap) parameter. For the high-energetic
beams (1-1.5 GeV/u), this formula gives an accurate description of σr , while for the lower
therapeutic energies it requires additional energy-dependent corrections. For the description of
the total reaction cross sections, the semi-empirical models of [Sihver et al., 1993; Kox et al.,
1987] can be applied. According to all of these models, there is no significant change for the
high-energetic beams with energies down to ≈100 MeV/u. With the further energy decrease,
these models predict the increase of σr due to the mechanisms like deep inelastic collisions or
fusion reactions.
One of the commonly accepted approaches to describe the energy dependence of the total
reaction cross-sections, in particular, implemented to the GSI in-house TPS TRiP98, is the one
suggested by [Tripathi et al., 1996, 1999]. According to it, the formula 1.6 can be expanded to
σr = pir
2
0

A1/3P + A
1/3
T −δE
2
1− Rc BEcm

. (1.7)
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The last multiplier in this equation describes the impact of Coulomb interaction at lower
energies, with Ecm (MeV) standing for colliding system center of mass energy, and B being the
Coulomb interaction barrier:
B = 1.44 ZpZt/R, (1.8)
where Zp and Zt are the charges of the projectile and the the target, respectively, and R is the
radius for evaluating the Coulomb barrier height. The transparency and Pauli blocking, relevant
for the intermediate and high energies, are taken into account via the energy-dependent δE
term. The semi-empirical Coulomb multiplier parameter Rc was introduced in order to adjust
the underestimated Coulomb energy effect for the light systems, e.g., p+4He, p+7Li or p+12C,
based on the existing experimental data.
Several measurements of the charge-changing reactions cross-sections for 16O beams with en-
ergies in the range of 200-700 MeV/u on water targets were published in the works of [Schardt
et al., 1996; Schall et al., 1996; MacCabee and Ritter, 1974], however, further measurements
in the therapeutic energy range are needed to benchmark the present TPSs.
1.1.2 Beam delivery
For successful treatment of the deep-seated tumors, the ions need to have a range of up to
approximately 30 cm (for example, to treat the prostate cancer). This requires their acceleration
to up to several hundred MeV/u and precise delivery to the desired location.
The acceleration of the ions for therapy nowadays is done with two kinds of accelerators,
cyclotrons, and synchrotrons. While being relatively compact, cyclotrons have a disadvantage
of offering only beams with constant energies and intensities. Thus, to achieve a desired dose
distribution in the target, the use of the beam energy degraders is required. In contrast, the syn-
chrotrons, used for the ion irradiation offer the active beam energy variation for each spill. The
price for that is the required complicated ion optics; however, according to [Jäkel et al., 2008],
synchrotrons are still expected to become a standard in radiotherapy after the improvement of
the techniques used to control the beam position and intensity.
Apart from delivering the beam to the desired depth, creating the spread-out Bragg peak
(SOBP) with its further shaping to the irregular tumor geometry is required to avoid the damage
to the tissues in its proximity. Two techniques, the passive and active beam scanning, are used
to achieve it.
The main idea of the passive beam delivery, which was historically the first method applied in
the ion beam therapy, is shown in Figure 1.5(a), taken from [Schardt et al., 2010]. The initially
narrow beam is broadened by the scattering system (typically with passive double scattering or
a magnetic wobbler [Kraft, 2000]) and spread by the range modulator to cover the whole length
of the tumor. The latter usually consists of rotating wheels of various thicknesses or a ridge filter
[Chu et al., 1993]. The further beam shift in depth is possible using the range shifter which is
a set of the absorber plates. After that, the unnecessarily large outer area of the beam is cut
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using the collimator, and the depth pattern is shaped to the tumor by using the compensator.
The disadvantage of this method is the dose deposition outside the tumor volume, which can be
decreased by, e.g., using the dynamic collimator of variable width.
(a)
(b)
Figure 1.5.: Beam delivery systems used in ion beam therapy. (a) Passive beam delivery system,
figure taken from [Schardt et al., 2010]. (b) Active beam delivery system, figure
taken from [Kraft, 2007].
The second method, active beam scanning, firstly developed at NIRS in Japan [Kanai et al.,
1983], is considered to be more advanced. The same publication of [Jäkel et al., 2008] predicts
it becoming a standard for RT. The principle of the active beam delivery system is illustrated in
Figure 1.5(b). The target volume is divided into several layers in depth to which the narrow pen-
cil beam of the corresponding energy will be delivered. Each layer is further divided into equally
sized subvolumes, and using the magnetic scanning in horizontal and vertical directions, each
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tumor layer can be scanned with the desired number of particles delivered sequentially to every
subvolume. This method offers more flexibility compared to the passive beam delivery since
avoids the manufacturing of any patient-specific compensators or collimators, and minimizes
the amount of material in the beam path thus reducing primary particle loss and production of
secondary particles [Schardt et al., 2010]. On the other hand, this method is more problem-
atic when it comes to treatment of moving tumors, such as lung cancer, due to the interplay
between the organ motion and the beam scanning. This may end up in the organs at risk (OAR)
or residual tissue receiving the dose that was initially expected to be delivered to the tumor.
1.1.3 Relative biological effectiveness
The damage caused by the radiation to a living cell is mainly determined by its location; the
most critical is the damage to the cell nucleus, in particular, the DNA molecules stored inside,
which may lead to cell death, mutations, or carcinogenesis. There are two pathways for the DNA
damage: the direct ionization of its components or the indirect damage through the hydroxyl
groups produced during the water radiolysis in the particle track. The direct damage is more
relevant for the high-LET radiation, such as the ion radiation, which has denser tracks than
low-LET radiation.
The difference in the biological effects caused by the X-ray radiation compared to ion beams
arise from the different microscopic dose distribution, as illustrated in Figure 1.6.
Photons transfer their energy by photoelectric or Compton processes, giving rise to the fol-
lowing ionization events and electron production. However, compared to the charged particle
interactions, these processes have low cross sections, leading to small numbers of ionization
events. The distribution of photons that has to deposit a relevant dose is random, leading to a
homogeneous dose distribution, as illustrated in Figure 1.6, top left. In case of the ion irradi-
ation, the deposited energy is extremely localized along the primary beam trajectory (Figures
1.6, top right and bottom left). The reason for a peaked dose distribution is the low energy
distribution of the largest part of emitted electrons, thus traveling at very short distance from
the track. The further increase of the ions energies leads to the decrease in their LET and broad-
ening their tracks, increasing the homogeneity of the dose distribution making it resemble the
photon dose distribution (Figure 1.6, bottom right).
To quantify the cellular or tissue response to irradiation, the concept of the relative biological
effectiveness, or RBE, is used. The RBE of the test radiation, e.g., ion radiation, is defined as
a ratio of the absorbed doses of a reference radiation and the test radiation, leading to the
same biological effect [Hall and Giaccia, 2006]. Most commonly 60Co γ -rays are taken as a
reference radiation [ICRU, 1993], while in many radiobiological experiments, the orthovoltage
X-rays serve this purpose.
1.1. Ion beam therapy 23
Figure 1.6.: Spatial microscopic dose distribution modeled for the different types of radiation:
X-ray (top left) and 12C ions of different energies for the same average microscopic
dose of 2 Gy. Figure taken from [Krämer et al., 2003].
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A common approach to define the RBE of the radiation of interest is comparing its influence
on the cell survival with the one of the conventional photon radiation using the clonogenic
survival curves. They describe the relationship between the absorbed dose of radiation and
the proportion of cells that remain able to reproduce, i.e., to divide and form colonies after
receiving this dose [Hall and Cox, 2010]. An example is shown in Figure 1.7, comparing the
survival curves for X-rays and a generic ion radiation. The curves plotted in a logarithmic scale
have a characteristic shouldered shape. To describe this behavior, the linear-quadratic (LQ)
approach is used, describing the cell survival as the following function of dose:
lnS = −  αD+ βD2 , (1.9)
with S standing for the cell survival after receiving the dose D. The α (Gy−1) and β (Gy−2) co-
efficients are the radiobiological cell- or tissue-specific constants, characterizing the initial slope
and the curvature of the survival curve, respectively, and their ratio emphasizes the difference
between early- and late-responding tissues in response to fractionated treatment [Hall and Cox,
2010]. For densely ionizing radiation, such as neutrons or high-LET ion radiation the survival
curves are described only by the α parameter and thus look like a straight line when plotted
on the logarithmic scale. It is important to mention that the linear and quadratic contributions
to the cell killing are equal at a dose D = α/β . While the LQ model is good at describing the
biological effect at low doses (not higher than ≈ 10 Gy), a more advanced approach is required
to account for the linear transition of the survival curve shape at a higher dose Dt . This issue
can be addressed by switching to the quadratic-linear model (LQ-L) [Astrahan, 2008]:
− ln(S) =
¨−  αD+ βD2 , D < Dt
−  αD+ βD2 + γ(D− Dt) , D ≥ Dt (1.10)
with γ being is the loge cell kill per Gy in the linear part of the survival curve at high doses.
As follows from the shape of the survival curve, the ratio of the ion and X-ray doses, leading to
the different survival levels, is different. In the current work, RBE10 of the ion beam is calculated
as a ratio a dose of X-ray radiation (DX ) to an ion dose (Dion), leading to the 10% cell survival:
RBE10 =
DX
Dion

S=10%
. (1.11)
Apart from the dependency on the dose or selected survival level, there is a strong dependency
on the LET of the particle: the RBE is increasing along the LET range, due to the increasing
ionization density leading to more complex damage [Barendsen, 1968; Friedrich et al., 2013b].
However, after a certain LET value, a decrease in the dependency is observed. The reason is
that for the more densely radiation the energy becomes ’wasted’ since the DNA damage sites
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Figure 1.7.: Definition of the relative bilological effectiveness based on the cell survival curves for
a given ion radiation (solid red line) and reference X-ray radiation (solid black line).
Different RBE values for survival levels of 10% and 1% are shown. Additionally, the
transition dose Dt is marked for the X-ray response curve.
are located too close to each other and thus not changing the outcome. This is the so called
"overkill" effect. Thus, it has the same efficiency per track but is less efficient per unit dose [Hall
and Cox, 2010]. Another experimentally demonstrated dependency [Furusawa et al., 2000],
arising from the differences in the energy distribution in the particle track, is the dependency on
the ion type: for the heavier ions, the maximum of the RBE-LET dependency is shifting towards
higher LET values. Apart from that, one has to keep in mind, that the biological effect is not
solely determined by the properties of radiation, but also by the characteristics of the cell line.
Irradiation of the cell lines with different repair capabilities might lead to very different RBE-LET
dependency behavior [Scholz, 2003].
1.1.4 Local effect model
For the estimation of the final effect of irradiation, the RBE has to be calculated for each
position inside the treatment field. One of the approaches for estimating the RBE is using
the local effect model (LEM), which is based on the knowledge of particle track structure and
the cell or tissue response to conventional photon radiation [Scholz and Kraft, 1996; Friedrich
et al., 2013a]. The principal assumption of the initial versions of the model (LEM I-III) was
the independence of the biological effect on the type of irradiation. Instead, it depends on the
deposited local dose. The cell nucleus was assumed to be the sensitive target, and the biological
effectiveness of ion was calculated based on the microscopic local dose distribution pattern of
ion traversals within it. The most recent version, LEM IV [Elsässer et al., 2010; Friedrich et al.,
2012], assumes the radiation effect to be dependent on the spatial distribution of the DNA
damage (essentially the double strand breaks (DSB) distribution) rather than the microscopic
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local dose distribution, and a similar DSB distribution leads to a same effect. However, the
recent study of [Grün et al., 2012] involving the treatment planning tests with patient data
demonstrated that the differences in the predicted absorbed doses leading to the same biological
outcome between versions I and IV for typical tumor volumes are less than 10%.
The input parameters for the RBE estimations with LEM IV are the X-ray response parameters
αX, βX and transitional dose Dt , characterizing the response of the cells to conventional photon
radiation according to the LQ-L approach [Scholz et al., 1997; Astrahan, 2008]. These parame-
ters are different for different cell lines or tissues as well as for varying experimental or clinical
endpoints.
All the calculations presented in this work were based on the RBE predictions done with LEM
IV, despite the LEM I still being used in clinics. The reason for using this version is that it allows
handling any type of particle species and energies, as well as for arbitrary αX/βX ratio, while
the LEM I was benchmarked only for 12C ions and for αX/βX ≈ 2 Gy.
1.1.5 TRiP98 treatment planning system
Planning software is an essential tool in treatment planning studies. Today the two ’com-
petitive’ types of the treatment planning systems (TPS) for the active beam scanning are being
developed. The first one is based on the Monte Carlo (MC) calculations of dose and particle
numbers due to their high accuracy and ability to consider emerging secondary radiation and
explicit 3-dimensional particle distribution [Grevillot et al., 2012; Mairani et al., 2013; Böhlen
et al., 2013], based on GEANT4 [Agostinelli et al., 2003] or FLUKA MC code [Battistoni et al.,
2007].
The disadvantages of the MC TPS are their calculation speed, complexity, and maintainability,
making them still not completely suitable for the clinical routine. The second TPS type is based
on fast analytic dose engines using pencil beam (PB) algorithms and is able to perform dose
optimization accounting for radiobiological effects caused by radiation. An example of such
TPS is TRiP98 (Treatment Planning for Particles), developed in 1998 [Krämer et al., 2000] to
provide the treatment plans for the GSI pilot project with 12C ions and raster scanning technique.
Nowadays it serves for research purposes in research centers in Heidelberg, Aarhus, and Lyon
and was a prototype for the commercial TPS such as Siemens SynGo/PT or RaySearch. The
simple scripting language of TRiP98 allows well documented repeated runs as well as batch
communications needed for systematic studies. This section describes the basics of treatment
planning with TRiP98, while the more specific details, related to the current work, will be
described in the Materials and Methods sections of the following chapters.
The overview of the general structure of the TPS is given in Figure 1.8. As mentioned above,
during the active beam scanning procedure the irradiated volume is virtually voxelized, and
every point is irradiated by a pencil beam formed by magnetic beam deflection system in the
lateral direction. The task of the TRiP98 code is to find an optimum set of accelerator energies
to cover the whole depth range and the corresponding particle numbers for each energy and
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spot position to achieve the prescribed dose. This procedure is called inverse planning. For the
imaging and localization of tumors in addition to other tasks the computed tomography (CT)
is used. The morphological information is usually stored in the VOXELPLAN format (developed
at the German Cancer Research Center (DKFZ) [Gademann et al., 1993]) and can be converted
from the commonly clinically used DICOM format. Recently also functional PET is providing
information on intratumor heterogeneity, which is essential for biologically adaptive treatment
planning.
The optimization process is performed in two steps. At first, the absorbed dose is considered
using input parameters like the number of fields, field weighting, and beam spot size. Second,
after an acceptable solution is found, the optimization with respect to the biologically effective
dose starts and voxel-specific RBE, and recently also OER values have to be calculated.
Figure 1.8.: A sketch of the general structure of TRiP98. Z stands for the particle charge and E
for its energy. The morphological maps and hypoxia maps are created externally by
external diagnostic tools. The base data input is loaded in form of tables.
The optimization is carried out by minimization of the objective function χ2
−→
N

[Krämer
et al., 2000; Gemmel et al., 2008]
χ2
−→
N

=
∑
i∈tar get
[Dp − Dia(−→N )]2
∆D2p
+
∑
i∈OAR
[Dmax − Dia(−→N )]2
∆D2max
Θ(Dia(
−→
N ) − Dmax) =min (1.12)
which is dependent on the number of particles within each raster scanner spot (components
of the vector
−→
N ). χ2
−→
N

accounts for the difference between the actual dose Dia and the
prescribed dose Dp at each voxel i. The second term in the equation, defined by the Heaviside
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function, is a ’penalty’ added to the function if the maximal allowed dose to the OAR Dmax
is exceeded and can be run through several OAR if needed. Dmax is defined by the user as a
fraction of prescribed dose:
Dmax = MDF × Dp, (1.13)
where MDF stands for maximal dose fraction and is normally defined in the range between 0.3
and 0.8. ∆Dp and∆Dmax in equation 1.12 are the adjustable dose tolerance coefficients defining
the weights of each two contributions and balancing the tumor coverage and OAR sparing:
∆Dp = fw × Dp / vw,T (1.14)
∆Dmax = fw × Dmax / vw,OAR. (1.15)
Here, fw reflects the allowed average deviation of actual dose from its prescribed value and is
usually set to 0.025, and vw,T and vw,OAR are the weight factors allowing to (de-)emphasize dose
deviations for the target or a given OAR, respectively.
Calculations of radiobiological effect are based on LEM IV model described in the previous
section. The loaded RBE tables store the data for each particle and its energy as their maximum
and intrinsic values, i.e., for single ion traversal. During the total effect calculation all the
contributions from the resulting particles in the mixed radiation field have to be considered
with appropriate algorithms [Krämer and Scholz, 2006].
To handle different ion modalities, physical base data are necessary. These comprise depth
dose profiles and tabulated particle energy spectra as a function of depth, in order to calculate
absorbed dose distributions and biological effects accordingly.
The most recent version of TRiP98, the so-called TRiP98-OER [Scifoni et al., 2013; Tinganelli
et al., 2015] accounts additionally for the target oxygenation status and requires the additional
input of the externally generated hypoxia maps. This way, the effect of the oxygen enhancement
ratio is accounted additionally at the step of the biological dose calculation. The problem of the
tumor hypoxia is addressed in the next section.
1.2 Tumor hypoxia
1.2.1 Definition and influence on the treatment planning
The condition of tumor hypoxia, leading to its chemo- and radioresistance, invasiveness, the
formation of metastases, altered metabolism and genomic instability [Brown, 2007; Wilson and
Hay, 2011], refers to the cases of tumors with insufficient molecular oxygen supply due to the
uncontrolled oncogene-driven proliferation of cancer cells [Eales et al., 2016]. The effect is
caused by the imbalance between the consumption and delivery of molecular oxygen due to the
interruptions of the blood flow through the tumor. Two pathways are usually defined (Figure
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1.9(a)): the chronic and the acute (cycling) [Hall and Giaccia, 2006; Hoppe-Seyler et al., 2017].
Chronic hypoxia occurs as a result of an increased tumor growth when the blood vessels can not
immediately reach the newly formed tumor regions (diffusion problem). The acute hypoxia is
usually defined as the result of a temporary occlusion of the blood vessel (perfusion problem).
(a) (b)
Figure 1.9.: (a) Chronic and acute hypoxia. Chronic hypoxia occurs due to increase distance be-
tween tumor blood vessel and tumor cells, resulting in an interrupted oxygen supply.
Red: oxygenated tumor cells, blue: hypoxic tumor cells. The acute, or cycling hypoxia
happens when the blood vessel gets occluded, e.g., through blood cell aggregates,
resulting in the fluctuating cycles of normoxia and hypoxia for surrounded tissues.
Adapted from [Hoppe-Seyler et al., 2017]. (b) Oxygen fixation hypothesis: a high
energy electron interacts with a water molecule, creating a highly-reactive hydroxyl
radical OH•. After its interaction with a DNA molecule, it can damage it by produc-
ing the DNA•. When the molecular oxygen is presented, a peroxy radical is formed
(DNA−OO•), which ′fixes′ the damage into a permanent irreparable state. Adapted
from [Grimes and Partridge, 2015] and [Hall and Giaccia, 2006].
Both pathways lead to an increased radioresistance of a tumor. The reason for that, still
quite debated in the radiobiological community, but one of the most accredited, is the so-called
’oxygen fixation of damage’ phenomenon at the chemical stage of the radiation interaction with
matter [von Sonntag, 1987; Hall and Giaccia, 2006; Grimes and Partridge, 2015]. The idea
of the oxygen fixation hypothesis is illustrated in Figure 1.9(b). Among the products of an
indirect action of radiation with water, the hydroxyl radicals (R•) are the main source of the
DNA base damage. Normally, this kind of radical damage can be chemically repaired. However,
the presence of the molecular oxygen (O2) may lead to the formation of peroxyl radicals, RO
•
2.
The damage caused by these type of radicals is much higher and almost impossible to for the cell
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to repair. Thus, under hypoxia, the indirect damage can be mainly restored, but in the presence
of molecular oxygen it will be likely made permanent, or ’fixed’.
In order to quantitatively estimate the dosimetric effect of hypoxia, the concept of oxygen
enhancement ratio (OER) is used, which is defined as a ratio of doses applied to normal and
hypoxic regions respectively, resulting in the same radiobiological effect (e.g. cell survival):
OERS =
D(pO2)
Dnormoxic

S
, (1.16)
where D(pO2) and Dnormoxic are the doses at a given oxygen concentration (or partial oxygen
pressure) and in the normoxic (partial oxygen pressure pO2 = 21%) condition, accordingly,
resulting in the same cell survival fraction S in the target.
Ion beam therapy is considered as an effective solution for tackling the problem of hypoxia.
Experimental studies of [Furusawa et al., 2000] showed the decrease of OER down to almost 1
for LET values of several hundreds keV/µm. The explanations for this effect are based on the
particle track structure [Alper and Bryant, 1974]. The high-LET particles have denser ionization
tracks, which increase the chances for radicals to interact between themselves. At the same
time, the chance of producing molecular oxygen in the track region is increased as well.
The decrease of OER values with increasing LET of the particle is described by the model
studies of [Wenzl and Wilkens, 2011; Stewart et al., 2011; Scifoni et al., 2013; Antonovic,
2014]. The key conclusion of all of them is that with the increase of the LET, depending on the
oxygen concentration in the region, one would expect a significant reduction (up to 2-3 times)
of dose, that has to be delivered to a tumor.
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Figure 1.10.: OER dependency on several values of partial oxygen pressure (pO2) and the LET of
the particle. Lines represent the model cuts from [Tinganelli et al., 2015].
1.2. Tumor hypoxia 31
Figure 1.10 shows the model cuts of the semi-empirical model developed earlier at GSI [Sci-
foni et al., 2013; Tinganelli et al., 2015], which describes the dependence of OER on the tissue
oxygenation level and the LET of the particle as
OER
 
pO2, LET

=
b
 
Ma+ LET
γ
/
 
a+ LET
γ
+ pO2
b+ pO2
, (1.17)
with pO2 standing for the partial oxygen pressure, LET - for the dose-averaged LET, and b, a,
γ, and M being semi-empirical parameters set to 0.25%, 8.27× 105, 3, and 2.7 for CHO cell line,
respectively. As follows from the model, the reduction of OER by a factor of 2 happens at LET
values of around 100 keV/µm almost independently on the target oxygenation. Thus, especially
for the highly hypoxic regions, applying the high-LET beams allow a significant reduction of the
delivered dose.
1.2.2 Hypoxia imaging
Since the presence of hypoxia can change the treatment outcome, possession of a reliable
tool for its visualization is crucial. The ideal tool for imaging hypoxia is expected to be non-
invasive, applicable to any tumor cite, amenable to repeated measures, able to distinguish the
perfusion- and diffusion-related hypoxia, non-toxic and simple to perform. Nowadays numerous
approaches to determine the oxygenation of the tissues are suggested, among them are:
• Positron emission tomography imaging, in particular, 18F fluoromisonidazole PET (FMISO-
PET), which is nowadays the most dominating among all the proposed strategies. It is a
non-invasive method based on the determination of the fluoromisonidazole uptake, act-
ing as a tracer, by the tissues [Cheney et al., 2014b; Eschmann et al., 2005]. Initially
the nitroimidazole compounds were developed for radiosensitizing hypoxic cells. They
have a nitro group (NO2), which under hypoxia can undergo a reduction to the amino
group (NH2), producing the intermediate highly reactive products that will bind to the
macromolecules inside the cell. Labeling the nitroimidazole with 18F allows one to identify
the bound product and thus the presence of hypoxia with PET [Horsman et al., 2012].
Nowadays this method is considered to be the most promising; however, the problem of
interpretation of the uptake data is still not completely solved [Toma-Das¸u et al., 2009;
Mena-Romano et al., 2015].
• Oxygen-enhanced Magnetic Resonance Imaging (MRI) [O’Connor et al., 2016], which can
be also promising since proton MRI is already actively used in the clinical routine. The
method is based on the sensitivity of the MRI longitudinal relaxation rate to changes in
the level of molecular oxygen dissolved in blood. In normoxia, hemoglobin molecules in
erythrocytes are saturated with oxygen and form oxyhemoglobin. Inhaling a gas with an
increased proportion of oxygen will not affect the proportion of oxyhemoglobin in blood,
but will alter only the amount of dissolved molecular oxygen in plasma. This will increase
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the tissue longitudinal relaxation rate, which is can be detected with MRI. In contrast,
inhalation of hyperoxic gas in hypoxia will lead to the formation of more oxyhemoglobin
molecules but almost with no impact on O2 amount in plasma, thus causing almost no
changes to the relaxation rate.
• Eppendorf oxygen electrode [Brizel et al., 1996], which, despite being a precise method,
is invasive, applicable only for the easily accessible tumors and requires considerable op-
erator skills.
• Perfusion estimation with PET using 15O-labeled water or with CT [Ng et al., 2009], which
allows identifying fluctuating hypoxia, however, do not give a complete picture of hypoxia
distribution.
• Identification of oxygen-responsive signaling mechanisms mediating the cellular responses
to hypoxia.
The latter two methods, despite being also quite promising, face a range of challenges. Among
them are the issue of penetration to cells distant from blood vessels and their toxicity.
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2 Experimental analysis of physical and
radiobiological properties of oxygen
beams
2.1 Introduction
The precise calculation of the delivered physical and RBE-weighted dose at any given target
spot requires the knowledge of the main beam properties. The basic input data required for
treatment planning with TRiP98 implies the knowledge of the beam depth-dose distribution,
fragment spectra, as well as its radiobiological properties and the behavior in hypoxic conditions
(where the 16O beams are mainly planned to be applied).
The current status of the beam model for 16O, based on the data for the underlying ions
and the recent measurements carried out earlier at GSI, was accessed through measuring the
beam-eye view and lateral dose profiles for an extended target irradiation. The radiobiologi-
cal measurements included an extensive series of RBE measurements for the CHO-K1 cell line,
determination of the oxygen enhancement ratio and the subsequent verification in hypoxia im-
plying the extended target irradiation.
The material presented in this chapter was published in [Sokol et al., 2017].
2.2 Materials and methods
2.2.1 Treatment planning
The general structure of the TRiP98 TPS was already described in the previous chapter. In
this section, all the treatment plans used for irradiations, radiobiological estimations and com-
parative studies were generated using TRiP98 in the proof-of-concept version including the OER
dose weighting [Scifoni et al., 2013]. In this version, the optimization is performed employing
the kill-painting approach, where the optimized quantity is no longer the RBE-weighted dose,
but a desired uniform survival level in the target. Thus, apart from the RBE, the system accounts
additionally for tumor oxygenation by including the OER values in the calculation of the biolog-
ical effects, both in forward and inverse planning. This way, the resulting calculated biological
dose is RBE- and OER-weighted.
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According to the low-dose approximation, introduced by [Krämer and Scholz, 2006], the
RBE-weighted dose can be calculated as
Dibio(
−→
N ) =
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where αx and βx describe the response to photon irradiation, αi and β i describe the response to
ion irradiation after dose averaging in the mixed field at voxel i. −→c Ti is the corresponding row
of the dose correlation matrix, characterizing the contribution of raster spots to a given voxel
[Krämer and Durante, 2010].
In order to introduce the OER as a dose-modifying factor, the ion response parameters had to
be modified as follows [Scifoni et al., 2013]:
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For enabling the dose calculation with 16O beams, the standard transport model was updated
with the recent primary 16O beam attenuation measurements (courtesy of G. Martino, GSI) and
the fragmentation data available for the lighter ions.
Since all the experiments were carried out using the CHO cell line, the LEM IV RBE tables for
it were produced based on the corresponding measured X-ray response data (see Appendix A).
2.2.1.1 Physical dose verification for extended target irradiation
For the physical dose verification experiments, an extended water target of 60 × 40 × 60 mm
centered at 82 mm in depth inside the water cube of 100 × 150 × 166 mm was emulated. Two
types of optimization were performed:
• physical (phys) - optimization for a uniform physical dose of 4 Gy;
• biological (bio) - optimization for a uniform RBE-weighted dose of 6.5 Gy for CHO cell
line.
The optimization was performed applying the plain gradient optimization algorithm
[Schmidt, 2005; Krämer et al., 2000]. For the RBE-weighted dose calculation, the low-dose
approach was used [Krämer and Scholz, 2006]. The following scanner/beam parameters were
considered:
• Nominal focus value for the beam spot (FWHM): 7 mm;
• Approximate spacing between subsequent peak positions (scanner stepsize in depth): 3
mm;
• Raster stepsize in x- and y-directions: 3 mm.
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2.2.1.2 Expected survival estimation
For each dose sample related to a particular survival curve, a separate plan was produced.
The field size was defined by the dimensions of a vessel used for culturing the cells (see the
following section).
The monoenergetic beams of 3, 146 and 280 MeV/u (with corresponding LET values of 670,
38 and 23 keV/µm) are available at UNILAC and HIT, respectively. For them, the cell curvival
was estimated in the beam entrance channel. To collect the survival data for the intermediate
LET values of 83 and 166 keV/µm, which are not available at any of these facilities, additional
experiments were conducted in an "extended" Bragg peak of 1 cm. This approach requires to
perform the survival calculations not for the pure LET values, but rather for the dose-averaged
LET values, defined as
LET = 〈LET〉D =
∑
i LETi Di∑
i Di
=
∑
i LET
2
i Fi∑
i LETi Fi
(2.4)
with Di dose and Fi fluence of the radiation component i.
The "extended" peak was modeled as a superposition of peaks created by the beams with five
selected energies. The shallower region in the resulting dose-averaged LET depth distribution
was chosen, to have some safety margins in measurements, related to the positioning of the
sample. The expected survival values were calculated at the selected position. The example of
the approach for the LET of 166 keV/µm is displayed in Figure 2.2.1.2.
For the estimation of the survival levels for the experiments with extended target irradiation,
the position of each cell sample in the treatment plan was calculated based on the knowledge of
the water equivalents of the setups’ materials. The corresponding data is provided in Appendix
B.
2.2.1.3 Hypoxia distribution modeling
To estimate the survival for the experiment in hypoxia presented in this chapter, an unevenly
oxygenated symmetric target geometry was emulated. Its size and the corresponding sizes of
hypoxic subvolumes were modeled according to the real sizes of the used cell culture vessels.
The total size of the simulated volume was 40 × 40 × 160 mm in water equivalent (WEQ) and
the target was centered at 80 mm depth (WEQ). By superimposing several phantom configura-
tions the following symmetric pO2 distribution along the beam direction z was emulated: 20%
for z < 62 mm and z > 98 mm, 0.5% for 62 ≤ z < 74 mm and 86 < z ≤ 98 mm, and 0% for
74 ≤ z ≤ 86 mm. These values of oxygenation were then used directly for the estimation of the
OER and dose calculations.
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(a) (b)
Figure 2.1.: Example of dose-averaged LET estimation for a particular position inside the ex-
tended Bragg peak of 1 cm. The Bragg peak corresponding to the dose of 0.5 Gy
in Figure (a) is a superposition of five peaks generated by beams with energies of
145.88, 150.24, 154.58, 158.78, 162.93 MeV/u. The corresponding dose-averaged
LET profile is shown in Figure (b). A relatively shallow position in the target region
(dashed lines) is chosen, and the corresponding dose-averaged LET (166 keV/µm)
and depth values are defined for further survival estimation.
2.2.2 Irradiation systems
3D physical dose verification, all the hypoxic irradiations, and part of the RBE measurements
were carried out in the experimental ’quality assurance’ (QA) room at HIT. A pool of monoen-
ergetic oxygen beams is available there [Kurz et al., 2012], with energies ranging from 103.77
up to 430 MeV/u, all of them delivered using a 3D intensity-controlled raster scanning system.
To assure the high accuracy of the dose delivery, prior to the start of irradiation procedure, the
calibration of the dose with the Farmer chamber has to be carried out. More information on the
procedure at HIT is given in Appendix C.
For the survival measurements at a given dose-averaged LET (LET) of 166 keV/µm and 83
keV/µm cell monolayers were placed in the middle of a 3D oxygen ion plan covering a depth
of 10 mm at a water equivalent depth of 35 mm, which was adjusted using a 30 mm or 25
mm acrylic glass (PMMA) bolus, accordingly. For measuring the survival for LET = 38 keV/µm
and 23 keV/µm, cells were irradiated with monoenergetic beams with energies of 146 and 280
MeV/u on target, respectively.
Radiobiological measurements for the energy of 3 MeV/u on target, corresponding to the LET
value of ≈ 670 keV/µm, were carried out at the Universal Linear Accelerator (UNILAC) at GSI.
The details on a specialized setup for this measurement are given below.
All the accompanying reference X-ray irradiations were performed at GSI with the Isovolt DS1
X-ray machine (Seifert, Ahrensberg, Germany) at a dose rate of 2 Gy/min and a peak voltage of
250 kV.
38 2. Experimental analysis of physical and radiobiological properties of oxygen beams
2.2.3 3D absorbed dose measurements
Measurements of the absorbed dose distribution were performed inside a water phantom
(MP3-P, PTW, Germany) using a set of pinpoint ionization chambers. Each chamber has a diam-
eter of 2.9 mm and a sensitive volume of 0.03 cm3. They are arranged in 6 staggered rows of
4 chambers, and the construction can be moved along x- and y-directions to achieve a higher
spatial resolution up to 0.1 mm (refer to [Karger et al., 1999] for more details). The scheme of
the configuration is shown in Figure 2.2.
Figure 2.2.: An example of the projection of the three-dimensional arrangement of 24 pin point
chambers for measuring the absorbed dose distribution onto the (x,z) plane. The
first and last two lines along z are staggered ±6 mm in y-direction.
2.2.4 Biological measurements
2.2.4.1 General procedure
The Chinese hamster ovary (CHO-K1) cell line was selected for the irradiation due to its sta-
bility and a short doubling time. The biological effects were accessed and quantified using a
clonogenic (colony forming) assay. Twenty-four hours prior to irradiation, cells were seeded in
monolayers with a concentration of ≈ 5 × 104 cells per sample. After the irradiation, approx-
imately 100 cells able to divide (clonogenically active) were re-seeded per T-25 (Falcon) tissue
culture flask (TCF) in 5 ml of medium (Ham’s F12 supplemented with 10% Fetal Bovine Serum
superior and 1% penicillin-streptomycin, Biochrom GmbH). To minimize the seeding error, for
each irradiated sample 3 corresponding TCF (triplicates) were prepared. After that, cells were
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incubated for seven days at 37 ◦C in a humidified atmosphere of 5 to 10% CO2 in air, then
stained with 1% methylene blue staining solution. Colonies containing more than 50 cells were
considered as survived and counted.
Depending on the experiment, irradiations were performed with three types of cell culture
vessels: T-25 flasks, Petri dishes, and specially designed rings [Tinganelli et al., 2013]. It
was previously demonstrated that these vessels could be used consistently for biological ef-
fect measurements [Tinganelli et al., 2015]. The first two vessels were used for the survival
measurements in normoxic conditions. The details on the irradiation in hypoxia are given be-
low.
2.2.4.2 Irradiation at UNILAC
For 16O ions with an energy of 3 MeV/u, the continuous slowing down approximation (CSDA)
range in water is expected to be ≈ 56 micron (estimated using LISE++ software [Tarasov and
Bazin, 2008]). This means that standard closed vessels, such as TCF, Petri dishes or well plates
are not applicable for irradiation with the low-energy particles since the beam will be absorbed
in the material. To overcome this issue, a particular setup is used at the UNILAC. It allows
irradiating the cell monolayers in open Petri dishes stored inside a special chamber. With the
help of a robotic system, the desired sample can be extracted from the magazine and placed
in front of the beam exit window. This method allows minimizing the beam energy losses,
since the only remaining material in the beam path are the 28 mm air gap and the 20 µm thin
medium film covering the cell monolayer. More details on the UNILAC irradiation procedure
can be found in [Kraft-Weyrather et al., 1989].
2.2.4.3 Irradiation in hypoxic conditions
For irradiating the cell monolayers in hypoxic conditions, GSI uses a specially designed and
patented [von Neubeck, 2006] combination of rings and chambers. The cells are cultivated onto
the hydrophilic side of a round piece of 25 µm thick gas permeable foil (biofolie 25 from Greiner
Bio One) equal to 47 µm water-equivalent (WEQ) thickness. The cell growth area size is 4.52
cm2. The foil is attached to a ring made out of polyvinyl-chloride, which is then filled with the
3 mm thick layer of growth medium and closed with a similar foil on the other side. After that,
the rings are kept into the dedicated hypoxic chamber (HC), in the quantities of one (single
HC), or three (triple HC). The photo of a single HC is shown in Figure 2.3. For reaching the
desired gas concentration, the chambers have to be flushed with the required gas mixture for
≈ 2 hours. The details of this procedure are reported in [Schicker et al., 2009] and [Tinganelli
et al., 2013]).
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Figure 2.3.: Photo of a single chamber (HC) used for irradiating cells at the desired level of pO2.
The ring sample containing the foil with the cell monolayer is fixed inside, and the
chamber is closed with a special lid preventing the gas exchange with the environ-
ment. Via the gas inlet and outlet, the chamber can be connected to the gas source,
and a constant gas mixture flow can be provided. For a single HC, the wall on one
side is thinner, and this side is normally used for irradiation to minimize the beam
loss and fragmentation in the wall material. In case of a symmetric triple HC, which
is usually used for the extended target irradiation, the walls are of equal thickness.
2.2.4.4 Extended hypoxic target irradiation
For testing the kill-painting approach for the treatment of hypoxic targets [Scifoni et al.,
2013; Tinganelli et al., 2015], modeling of an extended unevenly oxygenated target is needed.
To emulate a target with a hypoxic region in the center, a combined setup consisting of TCFs
and a triple HC was assembled, similar to the one described in [Tinganelli et al., 2015]. The
scheme of the phantom is shown in Figure 2.4(a). The entrance channel and target parts with
normal oxygenation level are imitated by the TCFs, and the triple HCs, gassed to the desired
oxygen concentrations (0.5% or 0% pO2), imitated the hypoxic regions. For increasing the
spatial resolution of the measurements, additional range shift was created by adding TCFs filled
with water and the polystyrene blocks to the setup, keeping the same overall WEQ length of the
phantom. The water equivalents of the materials used are presented in Appendix B. In total,
five different configurations of the phantom, each in two repetitions, were irradiated.
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(a)
(b)
Figure 2.4.: (a) A sketch of the phantom setup imitating the target with uneven oxygenation,
consisting of the triple hypoxic chamber and differently oriented tissue culture flasks.
Arrows mark the direction of the fields during the irradiation. (b) A photo of the
QA cave of HIT facility with three hypoxic phantoms positioned in front of the beam
exit window.
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2.3 Results and discussion
2.3.1 Physical dose verification
The result of the verification of the beam’s eye view depth-dose profiles for a target of 60 × 40
× 40 mm centered at a depth of 82 mm in water are shown in Figure 2.5. The circles represent
the average and the standard error (± SEM) of the two central pinpoint chambers of each row
of the configuration, described above. These errors are of an order of 1-3% and are smaller than
the data symbols. The numerical data for each point is given in Appendix D.
(a) (b)
Figure 2.5.: Verification of the absorbed dose in beam-eye view direction for a target volume
at 82 mm depth, covering a depth range of 60 mm. Plan is optimized for a (a) flat
RBE-weighted dose of 6.5 Gy (b) flat physical dose of 4 Gy. Circles correspond to
single pinpoint measurements, the line represents the TRiP98 prediction. The error
bars, representing the standard error (± SEM) of the two central pinpoint chambers
of each setup row, are smaller than the symbol size, thus cannot be distinguished.
For the absorbed dose profile presented in Figure 2.5(a) the treatment plan was optimized
for a uniform RBE-weighted (biological) target dose of 6.5 Gy. Since the dose-averaged LET
distribution is increasing towards the end of the beam range, the RBE distribution in depth is
increasing. Thus, to achieve a flat RBE-weighted dose profile, the absorbed dose profile has to
be decreasing towards the distal edge of the target. The difference between the calculated and
the measured dose is ≈ 1.3% in the entrance channel and ≈ 2.5% in the target region. For this
experiment, the dose in the fragmentation tail was not verified.
Figure 2.5(b) demonstrates the verification of a dose profile for a plan optimized for a pre-
scribed uniform absorbed (physical) dose of 4 Gy. The overall difference between the measured
data and the TRiP prediction is the following: ≈ 1.5% in the entrance channel, ≈ 3.3% in the
target and ≈ 9.2% at the distal fall-off. The presented data were collected over several indepen-
2.3. Results and discussion 43
dent experiments separated by several weeks, and the slight change in experimental conditions
can be the reason for an intrinsic measured dose fluctuation of around 5% in the target region.
For the treatment plan optimized for a uniform absorbed dose the additional analysis of the
lateral dose profiles at different depths was carried out. Four positions, corresponding to the
entrance channel (19.7 mm depth in water), the front part of the target (59.7 mm depth in
water), the distal part of the target (89.7 mm depth in water) and the fragmentation tail (129.7
mm depth in water) were chosen. The corresponding lateral profiles for the absorbed dose
are shown in Figure 2.6. In contrast to the previous measurements, each point is an indepen-
dent measurement of a single pinpoint chamber. In this case, the measured dose errors can be
estimated in a similar way as in [Schwaab et al., 2011] as
δDi =
p
Di/100 (2.5)
where Di is the value of the dose in Gy measured by the chamber.
The positioning error of the chambers in the horizontal direction is defined by their diameter
and the sensitive volume, which in case of the chambers of type TM31015 [PTW, 2017] with a
sensitive volume of 30 mm3 and an inner radius of 2.9 mm, is not expected to exceed the value
of ≈0.8 mm.
Although there is a good agreement with the TRiP calculation for the first two positions, the
discrepancy is slightly increasing with depth. In the region of the fragmentation tail, the dose
at the edges of the target volume is slightly underestimated. It needs to be further investi-
gated whether any beam components were not considered correctly in the calculation, or if it is
induced by experimental conditions.
2.3.2 Relative biological effectiveness
The level of the knowledge of the RBE values of oxygen beams at the moment of the start of
the current work could be described as poor. In 2013 the available RBE data for all the beams
were summarized by [Friedrich et al., 2013b] as a Particle Irradiation Data Ensemble (PIDE).
Here, twelve values of RBE10 for
16O beams are cited, with six values for CHO cell line [Scholz
et al., 1997; Scholz, 2003], four for V79 [Wulf et al., 1985], and one for C3H10T1/2 [Miller
et al., 1995], and M3-1 [Todd, 1975]. Thus, these data at the moment of the start of the current
project was more than ten years old. One additional value of RBE for the V79 cell line was
published in [Pathak et al., 2007], but not included to the PIDE. Regarding the CHO data, the
mentioned RBE values were calculated by [Friedrich et al., 2013b] based on the survival data
obtained using the procedure of plot digitalization since no numerical data was published in the
respective references.
In recent years, several more works reporting the RBE of 16O were published. In particular,
these are the works of [Tinganelli et al., 2013] who measured the effect of 140 keV/µm 16O on
the CHO cells while investigating the influence of hypoxia; [Habermehl et al., 2014] reported
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(a) (b)
(c) (d)
Figure 2.6.: Verification of the absorbed dose in the lateral direction at depths of (a) 19.7 mm,
(b) 59.7 mm, (c) 89.7 mm and (d) 129.7 mm. Circles correspond to the pinpoint
measurements, and the lines represent the TRiP98 predictions. The error bars, repre-
senting the intrinsic dose measurements errors, and the positioning uncertainties in
horizontal direction, are smaller than the symbol size, thus cannot be distinguished.
measurements for HEPG2, HEP3B, HUH7, and PLC cell lines, [Dokic et al., 2016] presented
one RBE value for a human alveolar adenocarcinoma cell line. However, based only on these
data, for none of the mentioned cell lines it is possible to estimate the behavior of the RBE-LET
dependency since not the entire energy range was covered.
Since the CHO-K1 cell line remains the most described cell line regarding the 16O RBE and is
one of the easiest cell lines in terms of handling, it was selected for performing the additional
survival measurements in order to verify the existing RBE10 values and to expand the dataset
for other LET values. The resulting pool of the corresponding survival curves including the
measured values and the fitted curves is shown in Figure 2.7 and the numerical data are given
in Appendix E. The X-ray measurements used for the further RBE estimations are shown in
black. As mentioned above in the Materials and Methods section, the measurements for the
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’reconstructed’ energies of 19.6 and 46.8 MeV/u correspond to the extended target irradiations
with LET = 166 keV/µm and 83 keV/µm, respectively.
Based on these measurements, the RBE10 were calculated as described in the previous chapter.
Using the LQ approach, the equation 1.11 can be rewritten as
Figure 2.7.: Survival fraction of the CHO-K1 cell line as a function of dose for 16O beams of differ-
ent residual energies. The reference X-ray is presented in black. The symbols and the
error bars represent the average ± SEM of two (for the energies of 3, 146 and 280
MeV/u) or three (for the energies of 19.6 and 46.8 MeV/u) independent repetitions.
Lines represent the fit of data. For the energies of 3, 19.6, and 46.8 MeV/u a linear
fit was applied; the curves for 146, 280 MeV/u, and the X-ray curve were fitted using
a linear-quadratic equation.
RBE10 =
βion
βX
· αX +
q
α2X − 4βX ln(0.1)
αion +
q
α2ion − 4βion ln(0.1)
(2.6)
where αion and βion are the LQ parameters for a given ion survival curve, and αX and βX are the
LQ X-ray parameters. This calculation is applicable for the energies of 146 and 280 MeV/u; for
the energies of 3, 19.6 and 46.8, where the survival is described as lnS = −αD, the equation
1.11 transforms into the ratio of the α parameters of the corresponding curves:
RBE10 =
αion
αX
. (2.7)
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The resulting values of the RBE10 are summarized in Table 2.1. The corresponding error δRBE10
was estimated based on the fitting errors for the corresponding α and β values for the survival
curves. According to the general trend observed for the RBE data in [Friedrich et al., 2013b], the
maximum of the RBE-LET dependency is expected to be established in the LET range of 100-400
keV/µm, and the measured data follows this trend. However, more precise estimation of the
position of this maximum is not possible since at HIT and GSI no corresponding monoenergetic
beams with the energies in the range of ≈ 10-40 MeV/u were available at the moment. Based
on the statistics from the same work [Friedrich et al., 2013b], the maximal values of the RBE
are expected to be in the range of 2-4; the maximal value observed in this work is 2.285±0.211
for the LET=166 keV/µm. However, it was measured for an extended target of 1 cm for a set
of five beams with the energies of 145.88, 150.24, 154.58, 158.78, and 162.93 MeV/u, which
brings the additional uncertainty to the position of this data point in Figure 2.8. The RBE value
for LET = 140 keV/µm 16O ions (2.27 ± 0.09) measured by [Tinganelli et al., 2013] also for an
extended target of 1 cm is in agreement with these measurements.
Table 2.1.: Numerical values for the RBE10 calculated based on the survival data, presented in
Figure 2.7 and in Appendix E. Additionally, for each LET value the linear-quadratic
parameters α and β for the corresponding survival curve are presented. For the LET
values of 83, 166, and 670 keV/µm (corresponding to the energies of 46.8, 19.6 and
3 MeV/u, accordingly) the linear fit was applied, thus no β values are given.
LET (keV/µm) RBE10
LQ parameters
α β
23 1.222 ± 0.197 0.170 ± 0.073 0.046 ± 0.011
38 1.640 ± 0.279 0.389 ± 0.093 0.044 ± 0.015
83 2.123 ± 0.243 0.734 ± 0.057 -
166 2.285 ± 0.211 0.794 ± 0.029 -
670 1.436 ± 0.132 0.497 ± 0.018 -
An additional comparison of the data for the CHO cell line measured in 1992-1993 was per-
formed. As can be seen from Figure 2.8, the older RBE values in the region of the intermediate
and high LET values tend to be higher, while there is a match with the recent data in the low-
and very high-LET regions within the error bars. There can be several reasons for the observed
discrepancy. First, in contrast to the recent dataset, in 1992-1993 all the RBE values were mea-
sured for monoenergetic beams. Second, slight differences in cell culturing procedure, such
as the cell growth surface or the medium used (the former protocol for the CHO cell line was
described by [Mitaroff et al., 1998]), can also contribute to this discrepancy.
The updated RBE-LET data pool, summarizing all the currently published data for 16O beams,
including the values presented above, is given in Figure 2.9.
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Figure 2.8.: A comparison of the calculated RBE10 values presented in Table 2.1 with the data
measured in 1992-1993, recently published in [Sokol et al., 2017]. The closed sym-
bols correspond to the monoenergetic irradiations, and the two open symbols cor-
respond to the dose-averaged LET values for the 1 cm target irradiation.
Figure 2.9.: Relative biological effectiveness of oxygen ions at 10% survival level as a function of
the particle LET for various cell lines. The data for V79 cell line is taken from [Wulf
et al., 1985; Pathak et al., 2007], for C3H10T1/2 - from [Miller et al., 1995], for M3-1
- from [Todd, 1975], for A549 - from [Dokic et al., 2016], for HEPG2, HEP3B, HUH7,
and PLC - from [Habermehl et al., 2014], for CHO - from [Tinganelli et al., 2013; Sokol
et al., 2017] and this work.
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2.3.3 Oxygen enhancement ratio
Since the main area of the potential application of 16O ions in therapy is expected to be the
treatment of hypoxic tumors, verification of the biological effect of 16O beams under this con-
dition is essential. As a part of the RBE measurements series described above, the survival
experiment for LET = 166 keV/µm was additionally repeated for the CHO cells in the anoxic
(0% pO2) condition. The comparison of the cell survival curves in normoxic and anoxic con-
ditions is presented in Figure 2.10. For both cases, the fitting was performed based on the LQ
approach with lnS = −αD. The numerical values for the corresponding points are given in
Appendix E. For most of the data points the sizes of the symbol are larger than the error bars;
thus the latter cannot be distinguished. The dashed line represents the fitted values of survival
prescribed by TRiP98. There is an agreement between the prediction and the measurements in
normoxic conditions within the error bars. At the same time, there is a small deviation between
the TPS calculations and the measurements for the anoxic case, which needs further investiga-
tion. However, the difference between the dose values, leading to the 10% survival, predicted
by TRiP98 and obtained from the fitting of experimental data, does not exceed 5%.
Figure 2.10.: Survival of CHO cells after irradiation with 16O ions of LET = 166 keV/µm in nor-
moxic (21% pO2) (blue) and anoxic (0% pO2) (red) conditions. The symbols and
solid lines represent the measured survival values and the linear fitting, accord-
ingly. The dashed lines correspond to the TRiP98 calculations. The error bars
represent the ± SEM of the three corresponding independent experiments. For
the dose values of 3 Gy in normoxic and 1, 3 and 4 Gy in anoxic conditions, the
sizes of the error bars are smaller than the symbol size and thus they cannot be
distinguished.
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Based on these measurements the OER10 at 10% survival level can be calculated as
OER10 =
D(pO2 = 0%)
Dnormoxic

S=10%
=
αnormoxic
αanoxic
, (2.8)
where αnormoxic and αanoxic are the radiobiological parameters for the survival curves in nor-
moxic and anoxic conditions, accordingly. The resulting OER10 are given in Table 2.2. The
measured value of OER of 1.33 ± 0.05 is in agreement with the TRiP98 prediction of 1.27
within the limits of the fitting error. From the match of this value with the model prediction of
[Scifoni et al., 2013], which was originally developed based on the data for 12C ions, the weak
dependency of the model on the particle type for the range of charge between 12C and 20Ne can
be concluded, as it was also found in [Furusawa et al., 2000].
Table 2.2.: The LQ parameters and the values of the OER10 for the survival curves in normoxic
and anoxic (0% pO2) conditions for 16O ions of LET = 166 keV/µm. Both measured
(fitted) and predicted (TRiP98) values are given.
pO2 αTRiP98 (Gy
−1) αfitted (Gy−1) OER10,TRiP98 OER10,measured
21% 0.800 0.794 ± 0.029
1.27 1.33 ± 0.05
0% 0.630 0.598 ± 0.002
2.3.4 Extended hypoxic target irradiation
Prior to the test irradiation of an unevenly oxygenated extended target, the irradiation of
the similar phantom consisting of tissue culture flasks and rings with two opposite 16O fields
in normoxic conditions was performed. The optimization was carried out for a uniform RBE-
weighted dose of 6.5 Gy. The resulting depth-survival profile along the central line is shown
in Figure 2.11. The error bars are the ± SEM of two independent repetitions. The numerical
values for each point are given in Appendix E. Both the measurements done with the tissue
culture flasks and the rings are in the good agreement with the TPS prediction for both the
entrance channel and the target regions within the error bars.
For a comprehensive testing of the biological effects caused by 16O in the presence of hypoxia,
the verification of the plan optimized for the same extended but partially hypoxic target was
performed. Using the kill-painting approach [Tinganelli et al., 2015], the treatment plan for the
CHO-K1 cell line was optimized for a uniform survival level in the target of 10%, corresponding
to the RBE- and OER-weighted dose of 6.5 Gy.
The resulting survival profile measurements in depth along the central line shown in Figure
2.12. The different color regions correspond to the differently oxygenated parts of the geometry.
Each measurement presented in the Figure is the average ±SEM of two independent repetitions;
the numerical data are provided in the Appendix E. In general, there is a good agreement with
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Figure 2.11.: Cell survival distribution in depth along the central line for a double-field plan opti-
mized for a flat RBE-weighted dose of 6.5 Gy or uniform target survival level of 10%
in normoxia. The dashed line corresponds to the TRiP98 prediction, the symbols -
to the measured survival values. Circles correspond to the values measured with
tissue culture flasks, triangles - with rings (in chambers). The target area is marked
with a row of crosses.
the TRiP98 prediction (solid red line) within the frames of the error bars in both entrance
channel and the target region, except the discrepancy, observed in the region with pO2 = 0.5%.
However, this discrepancy, in any case, does not exceed 10%. This uncertainty can occur due
to the difficulties of maintaining the intermediate level of hypoxia. A slighter increase in the
oxygenation can induce a slightly lower survival since the OER values are the most sensitive to
the variations of pO2 in in this range.
For the estimation of changes in cell survival in this region that might caused by the potential
fluctuations in phantom oxygenation, an additional analysis was carried out. The already pro-
duced raster files for the original phantom were taken as an input for a forward planning, and
the plans were recalculated for the new oxygenation distributions. For the latter, pO2 values
were kept as 0% in the target central region, 21% in peripheral target parts and residual tissue,
while the intermediate values in the target were changing from 0.1 to 0%. If pO2 exceeds 0.5%,
the recalculation will lead to the lower survival rates in this region, since the new OER values
will be lower than in the original plan. Similarly, when pO2 is lower than 0.5%, the recalculated
survival rates are expected to get higher, since in this case the negative effect of hypoxia will be
underestimated. The results of the analysis are given in Figure 2.13, which demonstrates the
dependency of the cell survival at a depth of 65 mm for the treatment plan on the oxygenation
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in the above mentioned region. As one can see from the plot, an increase of pO2 to 0.7-0.8%
leads to the drop of survival down to 0.09.
Figure 2.12.: Cell survival distribution in depth along the central line for a double-field plan op-
timized using the kill-painting approach for a uniform target survival level of 10%.
Shaded areas correspond to differently oxygenated regions: light red - to 0% pO2,
light yellow - to 0.5% pO2 , light green - to 21% pO2. Points and lines correspond
to the experimental results and the TRiP98 prediction for 12C (blue) previously pub-
lished in [Tinganelli et al., 2015] and 16O (red), accordingly. The error bars represent
the ± SEM of the two independent repetitions. The target area is marked with a
row of crosses.
In Figure 2.12 the additional comparison with a similar plan for 12C, performed by [Tinganelli
et al., 2015], is included. For the sake of clarity, the comparison with only the TRiP98 prediction
is performed, assuming the experimentally proven match of the corresponding experimental
data with the TPS calculation. As can be seen, with a given equal survival level of 10% in the
target region, 16O demonstrate the better sparing of the cells in the entrance channel (EC). For
a given plan, the improvement of the EC survival reaches the value of up to 10.2% at a depth of
≈ 30 mm compared to the plan optimized with 12C. However, at this point one should consider
the error bars for the corresponding experimental verification; thus, a more thorough analysis
of this potential difference between the ions is required and is a subject of the following chapter.
52 2. Experimental analysis of physical and radiobiological properties of oxygen beams
Figure 2.13.: Dependency of the cell survival at 65 mm depth for a plan, optimized for the pO2
distribution as shown in Figure 2.12, on the fluctuations of pO2 in the region 62 ≤
z < 74 mm.
2.3.5 Summary
The results presented in this chapter can be summarized as a first multi-scale and multi-effect
description of the 16O beams from a clinical point of view. The verification of physical dose
profiles together with the study of radiobiological properties of the beam were carried out.
The latter included the survival experiments for the cells in both normoxia and hypoxia, thus
covering the range of conditions where the 16O ions are expected to be applied.
The match between the pinpoint chamber measurements and the TRiP98 calculations for the
absorbed dose profiles in both beam-eye view and lateral directions prove the reliability of the
current status of the beam model. However, the slight discrepancy between the prediction and
measurements of the lateral beam profile in the region of the fragmentation tail needs further
investigation. For this particular level of the dose (less than 0.4 Gy) this deviation is negligible
and will not affect the quality of the treatment plan.
The RBE measurements for the CHO-K1 cell line expand the RBE-LET dataset available for
the 16O ions. The measured tendency for the RBE-LET dependency follows the general trend ob-
served by other groups for other ions, however, determining the value of the maximum requires
further experiments, possibly at alternative accelerator facilities. An accompanying cell survival
experiment in anoxic conditions prove both the TRiP98 radiobiological effects calculation as
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well as the applicability of the OER modeling suggested by [Tinganelli et al., 2015] also for the
16O ions.
The verification of the survival effect for an extended target irradiation was performed for
normally oxygenated and partially hypoxic targets involving the setup consisting of different
cell culture vessels. For both cases, TRiP98 was able to adequately predict the biological ef-
fect. Based on that, one can proceed with the further comparative treatment planning studies
involving 16O beams.
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3 Treatment planning studies with oxygen
beams
3.1 Introduction
The experimental verification of physical and radiobiological properties of 16O beams, pre-
sented in the previous chapter, demonstrates that the currently implemented biologically ef-
fective dose calculation algorithm accounts reasonably well for both physical and biological
characteristics of the beam, and proves the reliability of treatment plans produced with TRiP98.
The first indication of the potential benefit of 16O over 12C ions was demonstrated by the cal-
culations of Tommasino et al. [2015] who carried out a treatment planning test for an idealized
partially hypoxic box target. These estimations were confirmed by the experiment presented in
the previous chapter. However, considering the error bars of these measurements, the difference
in the measured survival values is not large and might be even questionable. Thus, on the one
hand, it is essential to perform an additional extended analysis in the same idealized geometry
to estimate the maximal possible effect of hypoxia on the plans for different ions. On the other
hand, this geometry is not realistic, and in case of a real patient plan with the complex irregular
shape of the target and organs at risk configuration, the effect of hypoxia can give a different
contribution to the outcome.
In this chapter, a series of extended tests, including a series of primary tests with the varying
impact of hypoxia on the plan, as well as several more realistic tests involving the patient data
for the typical cases of chordoma, adenoid cystic carcinoma, and prostate cancer, are presented.
The analysis of the results aimed at identifying the potential benefits of using oxygen ions for
radiotherapy was performed, both on pure geometrical considerations and in a realistic clinical
scenario.
3.2 Materials and methods
3.2.1 Model volume studies
A basic comparison of the entrance channel survival rates for 4He, 12C, and 16O ions was
performed for an idealized target geometry with varying impact of tumor hypoxia. The beam
model used to generate the plans with 4He was developed and validated recently by [Krämer
et al., 2016].
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A scenario similar to the experiment in hypoxia described in the previous chapter was used: a
rectangular target of 40 × 40 × 60 mm, placed at a depth of 80 mm in water was modeled, and
the entrance channel survival fraction values were calculated at 5 mm depth. The dimension of
the modeled CT was 100 × 100 × 80 voxels with a voxel size of 2 × 2 × 2 mm. The scheme of
the geometry showing the target and hypoxic regions configuration is shown in Figure 3.1. To
stay consistent with the experiment described in the previous chapter, for the RBE prediction,
the photon dose-response curve parameters αX = 0.216 and βX = 0.019 (see Appendix A) for
the CHO-K1 cell line, were chosen for both the target and the residual tissue. For each treatment
plan, a minimum number of particles per raster point was set to 11000 in order to be consistent
with the scanning monitor system capabilities. The water equivalent offset was kept as 2.89
mm which corresponds to the offset between the beam outlet and irradiation volume at HIT.
The following beam characteristics and scanner parameters were set: 6, 6, and 7 mm as the
beams spots focus values for 12C, 16O, and 4He ions, accordingly, and for all the beams the
scanner step size in x- and y-directions, and the approximate distance between the subsequent
peak positions were set to 3 mm also considering the ripple filter used for the heavier ions.
Since 12C and 16O beams show similar lateral scattering, it was decided to use the same widths
of these beams. The optimization was performed using the plain gradient method [Horcicka
et al., 2013] and the low-dose approximation for the biological dose calculation [Krämer and
Scholz, 2006]. For the sake of clarity, the tests were performed for only one pO2 value per target
(a symmetrical central region with oxygenation levels of pO2 = 0.5% or pO2 = 0.15% along
the beam direction). Three cases of prescribed survival in the target (ST): 6.5%, 10% and 30%
(which would correspond to flat RBE-weighted target doses of 4, 6.5 and 7.5 Gy of normoxic
plans with the same parameters, accordingly) were investigated. In total, for each combination
of ST and pO2 values 21 sample runs with a hypoxic region size step of 2 mm were performed
for each ion.
Figure 3.1.: Schematic representation of the geometry for entrance channel survival tests. The
normally oxygenated area of the simulated geometry is shown in light green. The
shaded area represents the target, where the area in light red corresponds to the
hypoxic (0.5 or 0.15% pO2) central part the size of which was varied between the
tests. The red dashed line depicts the center of geometry at z = 80 mm in water. The
two opposite fields are indicated by arrows.
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3.2.2 Patient plans
The base treatment data for the three pairs (later referred as cases A and B) of typical cases of
skull base chordoma, adenoid cystic carcinoma (ACC) and prostate cancer were taken from the
GSI pilot project patients archive. This includes the imaging files, such as CT and contours files,
and the TPS plans files used for treatment with 12C ions. From the latter ones, the technical
parameters such as the target centers, field configurations, and directions, were transferred to
the new plans to preserve the clinically reasonable conditions. The new treatment plans were
generated using the most recent base data for 1H, 4He, 12C, and 16O ions. The radiobiological
parameters were chosen as αX = 0.003 Gy
−1, βX = 0.0015 Gy−2, and transitional dose Dt =
22 Gy as in [Grün et al., 2015], based on the photon input parameters for late toxicity in the
central nervous system.
The focus values for the beam spots were chosen as 10, 7, 5, and 5 mm for 1H, 4He, 12C,
and 16O, respectively. To provide a reasonable ratio between the number of raster points and
the number of voxels (i.e. to avoid overdetermination), the scanner step sizes in x-, y-directions
and the approximate distance between the subsequent peak positions were set to 3 mm.
Each plan was optimized for two ion fields aiming at a flat RBE- (in normoxia) or RBE and
OER-weighted (in hypoxia) dose of 2 Gy per fraction. The CT parameters and beam angles,
exported from the original treatment plans of the pilot project are given in Table 3.1.
Table 3.1.: Characteristics of the treatment plans generated for the test involving the patient
plans for chordoma, adenoid cystic carcinoma and prostate cancer based on the plans
used during the GSI pilot project with 12C ions. The given geometry parameters are
corresponding total CT dimensions, voxel sizes (CT steps) in and the target center
position in x-, y-, and z -directions. Each plan was optimized for the two fields, thus
two corresponding couch angles are given.
Tumor
CT dimension CT steps, mm Target center, mm Couch angle
x y z x y z x y z Field 1 Field 2
Chordoma A 256 256 98 1.12 1.12 3 144.62 128.23 126.0 100 -100
Chordoma B 256 256 110 1.21 1.21 3 153.33 153.79 135.0 100 -100
ACC A 256 256 111 1.21 1.21 3 133.81 146.83 151.5 50 104
ACC B 256 256 114 1.12 1.12 3 176.43 130.05 171.0 -50 -104
Prostate A 256 256 113 1.95 1.95 3 228.96 245.07 192.0 90 -90
Prostate B 256 256 139 1.91 1.91 3 243.6 248.49 187.5 90 -90
For each plan, the organs in the proximity of the target volume were defined as organs at risk,
which implies applying the dose constraints (equation 1.12) to these structures. The constraints
defined by the clinicians during the pilot project were mainly preserved. For the plans for
chordoma the brainstem was selected and the maximal dose fraction (MDF), e.g., the maximal
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(a) (b)
Figure 3.2.: An example of a generated hypoxia distribution inside an adenoid cystic carcinoma
tumor. Two oval hypoxic regions consisting of an outer region with 0.5% pO2 oxy-
genation level, medium region with 0.15% pO2, and inner anoxic (0% pO2) region
were modeled inside the different parts of the tumor and are shown in gray colors.
The rest of the volume is normally oxygenated (21% pO2). The outer yellow line cor-
responds to patient’s head contour, the inner yellow lines marks the brainstem (a)
and additionally the eyes (b), and the white line marks the tumor contour. (a) Slice
46 out of 111. (b) Slice 55 out of 111.
dose allowed to the organ compared to the prescribed dose, was set 0.7. In case of the plan
for the ACC, case A, apart from the brainstem, the right optical nerve was selected as well.
The MDFs to both the brainstem and the nerve were set to 0.4. The weighting factors (WF),
characterizing the ’importance’ of this constraint were set to 0.9. For the case B, the original
plan did not imply any constraints to OAR, but for the current study the MDF and WF for the
brainstem were set to 0.5 and 0.9, respectively. For the prostate treatment plan, the rectum
and the bladder were located very close to the tumor. In the original plan, the corresponding
optimization constraints were set to 0.7 with a WF of 0.5. For the current tests, it was decided
to emphasize these organs, and the WF was reset to 1, however, to avoid sacrificing the tumor
coverage quality, the maximum dose fraction was increased to 0.8. For the prostate case B both
MDF and WF for the bladder and rectum were set to 0.8.
For performing the treatment planning tests with partially oxygenated tumors, artificial
FMISO-PET uptake data cubes were created using the external plug-in (courtesy of Prof. C.
Bert). The details on the pO2 handling procedure are given in Appendix F and are also relevant
for the next chapter. It was assumed the modeled hypoxia to be chronic, thus more likely oc-
curring in the central parts of the tumor. For each patient, the ellipsoidal hypoxic regions with
isocentric hypoxic parts with three or four levels of oxygenation were generated approximately
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in the center of the investigated tumor. For the tests with chordoma and prostate tumor, having
rather a regular shape between the different CT slices, one hypoxic region per tumor was mod-
eled. The both cases of ACC case had quite irregular shapes dramatically varying between the
slices. Thus, to simulate a higher contribution of hypoxia to the plan, it was decided to model
two regions in the different areas of the tumor for each of the geometries. An example of the
generated ellipsoidal hypoxia distribution and the tumor, OAR (brainstem) and eyes contours
for ACC case A are shown in Figure 3.2. Here, two slices of the patients’ head geometry in axial
view (outer yellow contour) at z = 16.5 and z = 14.1 cm are shown with the ACC tumor con-
tour outlined in white. For a given slice, the four-level pO2 distribution (21%, 0.5%, 0.15% and
0%) is shown in greyscale. The tumor sizes and the information about the modeled oxygenation
distribution for each of the six analyzed cases are given in Table 3.2.
Tumor type Total volume, pO2 Volume, %
cm3 % cm3 of the total volume
Skull base Case A 102.37 0 16.02 16
chordoma 0.15 24.53 24
21 61.82 60
Case B 126.48 0 10.73 8
0.15 8.41 7
0.5 16.87 13
21 90.46 72
Adenoid cystic Case A 213.19 0 6.48 3
carcinoma 0.15 15.08 7
0.5 28.83 14
21 162.80 76
Case B 115.75 0 4.85 4
0.15 5.49 5
0.5 11.60 10
21 93.8 81
Prostate Case A 148.99 0 30.06 20
tumor 0.15 15.18 10
0.5 18.10 12
21 85.66 58
Case B 52.43 0 5.66 11
0.15 7.54 14
0.5 12.87 25
21 26.36 50
Table 3.2.: Parameters of the hypoxia maps generated for the GSI pilot project patients plans.
Total volume stands for the total volume of the target. Two or three isocentric regions
with oxygenation decreasing towards its centers were created for every tumor. The
sum volumes of equally oxygenated tumor subvolumes and their ratio to the total
tumor volume are given in the last two columns.
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3.3 Results and discussion
3.3.1 Basic analysis accounting for target hypoxia
Despite the value of the ratio αX/βX ≈ 2 being more common in clinics, characterizing the late
toxicity in the CNS [Karger et al., 2006], it was decided to stick to the CHO cell line parameters
with αX/βX ≈ 11 to rather analyze the ’boundaries’ of the survival experiment described in the
previous chapter, than to get closer to clinical conditions in this study. The investigation of the
treatment plans with αX/βX ≈ 2 was left for the next step implying the analysis with realistic
patient geometries.
For this particular case of equal target and normal tissue radiosensitivities, there is no high
impact of RBE and the final survival effect is mainly modulated by the value of prescribed dose
and the impact of tumor hypoxia. In normoxic cases the calculated RBE- and OER-weighted
dose and resulting cell damage in the EC is justified to be the lowest for 4He ions, that deliver
the lowest physical dose and produce fewer fragments, compared to 12C and 16O; this is in
agreement with a recent study by Grün et al. [2015]. The result of the optimization for three
ions for a normally oxygenated target for a prescribed RBE-weighted dose is given in Figure
3.3.1.
(a) (b)
Figure 3.3.: Depth-dose profiles for oxygen (solid green line), carbon (dashed blue line), and
helium (dot-dashed red line) ions plans optimized for a unform RBE-weighted dose
of 6.5 Gy in the 60 mm target for the CHO-K1 cell line with αX/βX ≈ 11. (a) RBE-
weighted dose profile. (b) Survival profile.
The survival levels for each plan were extracted in the region of the entrance channel at 5
mm depth and are given in Appendix G. For several calculated data points the general survival
decrease trend is broken, and for the slightly higher hypoxic contribution, the calculated EC
survival can be lower than for the smaller hypoxic region size. This might happen because
of the different relative locations of the voxels borders or centers and the borders of hypoxic
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regions. Additionally, there is generally some ’freedom’ for the optimization since no addi-
tional constraints for the planning were introduced. However, despite these fluctuations, the
clear trend in the survival decreases for each ion, prescribed survival and oxygenations can be
distinguished.
The resulting trends of the survival decrease at 5 mm depth in the entrance channel for each
combination of expected target survival and the pO2 level in the hypoxic region are shown in
Figure 3.4. In case of a smaller contribution of hypoxia (¯ 1-2 cm region) the effect is similar
to the one in absence of hypoxia, when 4He generally demonstrate the lowest cell kill in the
entrance channel, while 16O behaves similar or only slightly worse than 12C ions. With the
further increase of the size of the hypoxic region, the trend lines start to cross. The first crossing
point normally occurs for the 16O and 12C lines’, meaning that sparing of healthy tissue by using
16O ions becomes more efficient. The crossing with the 4He line occurs later or, as can be noticed
from Figures 3.4(a) and 3.4(b), these two lines can cross only at the very high values of hypoxic
region size (Figure 3.4(a)) or become indistinguishable within the confidence interval. In this
case, the prescribed dose is the highest among the analyzed cases, and in normoxic case, the
difference between 4He and the heavier ions is the largest. Thus, this initial benefit seems to
outweigh the effect of hypoxia with further decrease of oxygenation, even for a relatively large
region. Thus, when one aims at a higher cell killing after a single irradiation (cell survival <
10%) in the target, switching to heavier ions seems to be not justified: compared to lighter ions,
the use of 16O increases the survival in the EC by less than 4% and only when the significant
part of tumor is hypoxic. However, applying such high doses is not very common in clinics, and
the analysis of the plans with a lower prescribed biological doses deserves more attention.
Figures 3.4(c) and 3.4(d) represent the results obtained for the treatment plans for the same
prescribed dose as in the experiment described in the previous chapter. While for the less
hypoxic tumors (pO2 = 0.5%) switching to the heavier modalities remain questionable, for the
lower levels of oxygenation the improvement in the entrance channel survival can reach up to
≈ 10-12% but only when the major part of the target is hypoxic.
The most pronounced effect can be observed for the lowest of the prescribed doses that were
tested (4 Gy, figures 3.4(e) and 3.4(f)). In this case, the difference between the ions in the nor-
moxic case is less significant. With increasing size of the central hypoxic region and decreasing
its oxygenation, the benefit of 16O ions over lighter ions becomes more pronounced since the
effect of lower OER is more likely to outweigh the initial negative effect of nuclear fragmenta-
tion. For higher (0.5%) oxygenation levels, the usage of heavier modalities is still not justified
unless a significant part of the tumor is hypoxic. In this case, according to the model of Scifoni
et al. [2013], the maximal possible OER values will not exceed ≈ 1.7. However, for the lower
(0.10 - 0.2%) pO2 values the OER may increase up to ≈ 2.5. With 16O demonstrating the dose-
averaged LET of ≈ 100 keV/µm in the hypoxic region, one should expect the reduction of the
OER by approximately a factor of two. That may lead to a relative increase of survival in the
entrance channel by up to ≈ 13-15% and its pronounced benefit when already less than a half
of the target is hypoxic.
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(a) (b)
(c) (d)
(e) (f)
Figure 3.4.: Dependency of the survival rate calculated by TRiP98 at a depth of 5 mm (entrance
channel) on the size of the central hypoxic target region for 4He (red dash-dot line),
12C (blue dashed line) and 16O (green solid line) ions for a fixed target survival rate.
The corresponding couples of thin lines of the same style enclose the 95% confidence
intervals for each dependency. (a) ST = 6.5%, pO2 = 0.5%, (b) ST = 6.5%, pO2 = 0.15%,
(c) ST = 10%, pO2 = 0.5%, (d) ST = 10%, pO2 = 0.15%, (e) ST = 30%, pO2 = 0.5%, (f)
ST = 30%, pO2 = 0.15%. The target of 60 mm is centered at a depth of 80 mm.
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3.3.2 Tumor control probability analysis
In order to achieve a better therapeutic outcome, the treatment is often divided into several
fractions, so the dose to the patient is delivered in smaller portions during the period of several
weeks. This allows better sparing of normal tissue through repair and repopulation of its cells
during the time between fractions. In this section, the parameters, related to the fractionated
treatment, are analyzed based on the results presented in the previous section.
Another level of the quantitative assessment of the treatment plan is the estimation of the
tumor control probability (TCP), which describes the probability that a given dose of radiation
will provide tumor control or eradication of specific tumor cells [Brady and Yaeger, 2013]. In
this section, based on the EC survival data from the previous section, a TCP analysis, comparing
OER-optimized plans for the different ions with the normoxic plan, was performed.
In the case of inhomogeneous cell survival in a voxelized target, the Poissonial model of TCP
TCP = e−NS(D) (3.1)
with N denoting the initial number of clonogenically active cells and S - the survival fraction
after the dose D, can be rewritten as
TCP =
N∏
i=1
e−(Si)nνiρi (3.2)
where n is the number of fractions, Si is the survival in each voxel i of volume νi, ρi is the
density of cells per unit volume, and N is the total number of voxels. Applying the ’normoxic’
plan for a partially hypoxic tumor will lead to the presence of different survival regions in it
after the irradiation. For this case, assuming the two regions of different oxygenation in the
tumor as in the treatment planning tests in previous section, and voxels equal in terms of size ν
and cells contained ρ, the equation can be simplified to the following:
TCPnon−opt = e
−ρν

Sn1
Vnormox
Vt
+ Sn2
Vhypox
Vt

(3.3)
Vnormox + Vhypox = Vt (3.4)
where S1 is the planned survival and S2 > S1 is the resulting increased survival (’underkill’).
The example of such an optimization resulting in an uneven survival for two different values of
pO2 in the hypoxic region is shown in Figure 3.5. At the same time, for the OER-optimized plan
the resulting survival is expected to be uniform and the equation 3.2 can be rewritten as
TCPoer−opt = e−ρνS
n
1 . (3.5)
3.3. Results and discussion 63
At this point is should be mentioned that for the calculations in this sections the small fluc-
tuations in the cell survival at the different regions interfaces, caused by the drastic changes of
target oxygenation, were neglected. Thus, for the further calculation in this section, only one
survival level inside the target is assumed for an OER-optimized plan.
Figure 3.5.: Depth-dose survival profiles for 4He ions plans optimized for a unform RBE-weighted
dose of 4 Gy in the 60 mm target for the CHO-K1 cell line with αX−ray/βX−ray ≈ 11,
not accounting for the presence of hypoxia in the center of the target (the region
shaded with light red color). Depending on its oxygenation, with the same survival
in the entrance channel, this results in the different peaks in the survival distribution
in the target (solid line - 0.5% pO2, dashed line - 0.15% pO2).
For the planning tests in the previous section, the voxel volume was 8 mm3 and the target
is 20 × 20 × 30 voxels, thus ν = 96000 mm3. The cell density per voxel was taken as 104 as
in [Tinganelli et al., 2015]. Using a similar approach, the comparison of normoxic and OER-
optimized plans for different ions can be made using the concept of the biologically effective
dose (BED) in the entrance channel [Hall and Giaccia, 2006]. This quantity is commonly used
in radiotherapy for comparison of different fractionation regimes.
The biological effect after n fractions, delivering the total dose D can be calculated using the
LQ approach as
E = − lnS = αD+ βD2, (3.6)
where S is the cell survival, and α and β are the radiobiological parameters for a reference
survival curve for the analyzed cell line. At the same time, the equation 3.6 can we written as
E = n
 
αd + βd2

= α n d

1+
d
α/β

, (3.7)
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where d stands for the dose per single fraction and D = nd. The quantity E/α is called the
biologically effective dose:
BED = nd

1+
d
α/β

. (3.8)
Thus, with the same dose per fraction, the relation between the numbers of fractions that are
required to get the same survival in the entrance channel for the non-OER optimized (normoxic)
plan (nnormox) and the plan accounting for oxygenation (nOER−opt) can be expressed as
nnon−optSnon−opt = nOER−optSOER−opt (3.9)
For the comparative analysis of the TCP, the data from the previous section for a prescribed
biological ’normoxic’ dose of 4 Gy was taken, since it is the lowest and closest to the clinical
conditions. Since 4He demonstrates the lowest cell kill in the entrance channel in case of the
normoxic tumor or a plan optimized not accounting for tumor hypoxia, the corresponding plan
was chosen as a reference for the comparison with all the following OER-optimized plans. The
TCP analysis was performed with two pO2 values of 0.5% and 0.15% for two sizes of hypoxic
regions: 1 cm where the impact of hypoxia is very low and 5 cm when the observed effect is
significant. Thus, the values of S1 and S2 were set to 0.31 and 0.49 for pO2=0.5% and 0.31
and 0.59 for pO2=0.15%, accordingly. The results of the BED calculations at 5 mm depth in the
entrance channel are given in Figure 3.6.
From all the four analyzed cases can be expected an improvement in the local control using
an OER-optimized plan instead of the normoxic one. However, for small sizes of the hypoxic
regions this improvement is not strongly dependent on the ion type, as seen from the Figures
3.6(a) and 3.6(c). In particular, the ratio of the BED leading to the TCP of 50% for the tumor
with the 1 cm of pO2=0.5% region for the normoxic and OER-optimized plans is 1.36, 1.26,
and 1.20 for 4He, 12C and 16O, respectively (Figure 3.6(a)). For the same region size but with
the decreased oxygenation of 0.15% the corresponding values change to 1.68, 1.63, and 1.59
(Figure 3.6(c)), accordingly. Here one should keep in mind the above-mentioned fluctuation
in the entrance survival levels, which might add a ≈10% uncertainty to these values. With
the increase of OER contribution to the optimization, the ratio of BED for the normoxic and the
OER-optimized plans is decreasing, but its values become well distinguished between the lighter
and heavier ions (Figures 3.6(b) and 3.6(d)). The corresponding ratio of the BED leading to the
TCP of 50% is 1.02, 1.04, and 1.14 for 4He, 12C and 16O ions, respectively, for the tumor with a
5 cm of pO2=0.5% region and 1.11, 1.12, and 1.3, respectively, for the tumor with the 5 cm of
pO2=0.15% region.
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(a) (b)
(c) (d)
Figure 3.6.: Comparison of the tumor control probability (TCP) as a function of a biologically
effective dose (BED) in the entrance channel for the 4He ion plan not accounting
for the presence of hypoxia (normoxic) and the OER-optimized plans for 4He, 12C
and 16O ions for different contributions of tumor hypoxia. The prescribed uniform
biological dose per fraction to a rectangular partially hypoxic target of 6 cm was
4 Gy. The calculations were performed based on the calculated cell survival data
provided in Appendix F. The BED was calculated at 5 mm depth and indicates the
similar damage to the residual tissue after applying several fractions of each plan
to the target. (a) 1 cm central target region with 0.5% pO2. (b) 5 cm central target
region with 0.5% pO2. (c) 1 cm central target region with 0.15% pO2. (d) 5 cm central
target region with 0.15% pO2.
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3.3.3 Analysis of patient plans from GSI pilot project
In the previous section the geometry of the target region was not varying between the CT
slices, thus not leading to sharp dose changes, neither in proximal nor in lateral directions. In
reality, the tumor is irregular and never has a similar shape for every two neighboring cuts.
This might affect the outcome of the treatment planning. For example, if the size of the tumor
is decreasing from one CT slice to the next one, the dose to the residual tissue in the smaller
cut will be increased due to the fragmentation or scattering of ions in the target region in the
previous slice.
The previous analysis aimed at the estimation of the effect in the beam entrance channel.
Knowledge of the damage to the tissue and structures in this region is important, however,
in the realistic treatment plans more attention, apart from the tumor coverage, is paid to the
damage caused to the critical structures (OAR). The clinicians select the field configuration in
order to avoid these structures being located in the beam entrance channel. Thus, the structures
marked OARs tend to receive the dose arising mainly from the lateral scattering of the primary
beam and its fragments. Accessing the damage to such structures was a part of the presented
analysis.
This section describes the additional treatment plan analysis involving real patient geome-
tries. The result of the optimization was assessed by means of dose-volume histograms (DVH),
that included the information about the target dose, the dose to the OARs (brainstem in case
of chordoma and ACC tumors or rectum and bladder in case of the prostate cancer) and the
residual tissue. Additionally, the maximal, minimum and mean dose values received by these
volumes, were assessed. In case of prostate cancer, the additional analysis of the dose received
by one of the two hip joints was performed. This way, the dose received by the OARs and by
residual tissue was analyzed together with the quality of the target coverage.
The resulting two-dimensional RBE- and OER-weighted dose distributions at three central CT
cuts (axial, coronal and sagittal) and the corresponding dose-volume histograms for the two
cases of medium-sized skull base chordomas are shown in Figures 3.7 (case A) and 3.8 (case
B), respectively. There the contours of the emulated isocentric hypoxic regions are additionally
outlined with the dotted lines. The tumors in the two analyzed cases are of comparable sizes
and shapes. However, the ratio of volumes with the decreased oxygenation to the normoxic
volumes is different. The first tumor is more hypoxic, as can be seen from the Table 3.2: apart
from the smaller normally oxygenated part, only the regions with pO2 = 0.15% and 0% are
present, while in the case B there is a region with an increased pO2 value of 0.5%.
As can be seen from the DVHs for the targets, in normoxic case all the four modalities demon-
strate similar tumor coverage for both cases. Heavier ions (12C and 16O), however, can be more
beneficial regarding the lowest standard deviation from the corresponding target dose mean
values. In the first case they are 0.04 and 0.03 Gy compared to 0.05 and 0.06 Gy for 4He and
1H, respectively. For the second tumor the deviations are 0.04, 0.05, 0.06, and 0.09 for 16O, 12C,
4He, and 16H, respectively. The presence of the hypoxia significantly affects the tumor coverage
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by the lighter ions, especially protons. For them, the standard deviation increases up to 0.28
and 0.19 Gy in cases A and B, respectively, which is almost 10% and 20% of the prescribed dose.
In contrast, 16O ion plan is least affected by the presence of hypoxia.
From the Figures 3.7(a) and 3.8(a) can be observed that, considering the field configuration
and the relative positions of the tumor and the brainstem, the dose to the latter will be a result
of the particle scattering and fragmentation. Since protons demonstrate the highest lateral
scattering, this can be the explanation for the dose delivered to the brainstem being the highest
for them in normoxic case. On the other hand, the other explanation for the highest dose for
protons can be the initial beam spot size, which is the largest for them. The intermediate mean
dose delivered by 16O ions (0.264 Gy (case A) and 0.304 Gy (case B), respectively) compared
to the doses delivered by 12C and 4He (0.181 and 0.354 Gy in case A, 0.238 and 0.426 Gy in
case B, respectively), might be explained by the lowest lateral scattering, however, the highest
contribution of nuclear fragmentation among the four ions.
The DVHs demonstrate that the mean dose to the brainstem is almost independent on the
oxygenation status of the tumor for both cases. This statement should be addressed with caution
for protons, since with the observed inadequate tumor coverage the overall suitability of the plan
is questionable.
Table 3.3 summarizes the minimal, maximal, and mean relative doses delivered to the target,
brainstem and residual tissue for each ion, compared to the prescribed RBE- and OER-weighted
target dose of 2 Gy. While the numbers for the average brainstem doses confirm the trend
observed from the DVH, another important trend can be observed for the values of the maximal
doses to both the brainstem and residual tissue. In case of the brainstem, this dose might be
received by its parts situated in the proximity to the tumor and which can be considered as the
'hotspots'. Since the total volume that received this very high dose is significantly lower than the
total volume of the brainstem, these hotspots have almost no impact on the value of the mean
dose. However, at the same time, this parameter should be considered for accessing the risk of
damaging serial organs [Brady and Yaeger, 2013].
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(a)
(b)
Figure 3.7.: Biologically optimized two-field plan for a partially hypoxic skull base chordoma,
case A. (a) RBE- and OER-optimized biological dose distributions in axial, coronal
and sagittal planes. The solid white line marks the tumor, yellow lines - brainstem
(OAR) and eyes (on the first cut). The two isocentric hypoxic regions with 0% and
0.15% pO2 are marked with dotted white lines. The scale represents the relative dose
received by the tissue, compared to the prescribed biological dose of 2 Gy. (b) DVHs
for the target, brainstem and residual tissue (RT) for the plans with 16O (red), 12C
(blue), 4He (green), and 1H (black) for the cases of hypoxic (solid line) and normoxic
(dashed line) chordoma.
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(a)
(b)
Figure 3.8.: Biologically optimized two-field plan for a partially hypoxic skull base chordoma,
case B. (a) RBE- and OER-optimized biological dose distributions in axial, coronal
and sagittal planes. The solid white line marks the tumor, yellow lines - brainstem
(OAR) and eyes (on the first cut). The two isocentric hypoxic regions with 0% and
0.15% pO2 are marked with dotted white lines. The scale represents the relative dose
received by the tissue, compared to the prescribed biological dose of 2 Gy. (b) DVHs
for the target, brainstem and residual tissue (RT) for the plans with 16O (red), 12C
(blue), 4He (green), and 1H (black) for the cases of hypoxic (solid line) and normoxic
(dashed line) chordoma.
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(a) (b)
Figure 3.9.: Maximal relative dose received by the brainstem for the plans optimized for a 2 Gy
RBE- and OER-weighted dose for a normoxic (N) or partially hypoxic (H) skull base
chordoma irradiated with 16O, 12C, 4He, or 1H. (a) - case A, (b) - case B.
The histograms, comparing the maximal doses received by the brainstem in hypoxic in nor-
moxic conditions for the four ions for cases A and B, are shown in Figures 3.9(a) and 3.9(b),
respectively. In the case A, while in normoxia this parameter is not noticeably varying between
the ions, with the decrease of target oxygenation the heaviest ions demonstrate a clear benefit
in the form of the lowest values. The maximal dose delivered by 16O is 5.5% and 16.6% lower
than the maximal dose for 12C and 4He, accordingly. The similar trend for the maximal dose can
also be observed for the residual tissue (Table 3.3). The corresponding improvement from using
16O is 9.3% and 23% compared to 12C and 4He, accordingly. For the second tumor, there is no
such significant difference in the values of the maximal dose to the brainstem (Figure 3.9(b))
between 16O, 12C and 4He plans. Moreover, one can also notice almost no difference between
the respective doses in normoxia in hypoxia.
The similar analysis was carried out for the ACC tumors. The two analyzed cases of ACC
tumors had an almost two-fold difference in sizes (≈213 and ≈116 cm3) but similar level of
oxygenation (≈80% of the total volume was assumed to be normoxic, the rest had four levels
of decreased oxygenation). Compared to chordoma, both tumors were located closer to the
head surface and were irradiated at similar angles with two fields at 50 and 104 or -50 and
-104 degrees, respectively. The RBE- and OER-weighted dose distributions at three central
orthogonal CT cuts and the dose-volume histograms for cases A and B are displayed in Figures
3.10 and 3.11, respectively. Compared to both chordoma cases, these tumors had more irregular
shapes and thus there were regions of the residual tissue inbetween that received the increased
dose according to the optimization results. In both cases, the mean dose to the residual tissue
appears to be slightly higher than in case of chordomas. Regarding the tumor coverage, the
trend is the same as in case of chordomas: 16O ion demonstrate the best tumor coverage and
the least dependence on the presence of hypoxia. The numerical values of the relative doses
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to the tumor, brainstem and residual tissue for the ACC case are given below in the Table 3.4.
Since protons demonstrate the similar scenario for the tumor coverage in hypoxia as for the
chordoma plan, they are not mentioned in the further comparison.
For this plan, the higher constraints to the OAR were applied (the maximal allowed dose
fraction to the brainstem was set to 0.4 for case A and 0.5 for case B). Thus, as can be seen from
the Figures 3.10(b) 3.11(b) and Table 3.4, the respective average doses are relatively low. For
both cases, 12C ions deliver the lowest mean dose for both normoxic and hypoxic conditions.
The analysis of the maximal doses summarized in Figure 3.12 also leave 12C as a best choice for
both cases of oxygenation. It is also possible to note that the trends for the doses to the OAR
remain independent on the target size, when the other plan parameters remain similar.
A possible explanation to the difference in the trend for the maximal doses for the two ana-
lyzed tumor types can be the relative position of the target and the OAR. In case of chordoma
for the given fields configuration, the brainstem is a lateral OAR, which implies that one should
expect it to receive the dose produced mainly by the scattered particles and initial beam width.
Since at these depths 16O and 12C experience comparable scattering Schardt et al. [2010], the
lower required dose of 16O might lead to the decrease of the maximal dose in the brainstem. For
the given cases of ACC, the brainstem is located partially in the fragmentation tail of one of the
two fields. Since 16O ions generate more fragments than 12C, even the decreased required dose
in hypoxia might not overweight this effect, leaving 12C ions the best option for this particular
case of ACC. As follows from the numerical values of maximal doses for the brainstem, this
parameter is almost not affected by this level of tumor hypoxia, disregarding the tumor size. At
this step, only one out of the four analyzed tumor cases (chordoma, case A) with the smallest
ratio of the normally oxygenated tissue to the total tumor volume (≈60%) demonstrated the
distinguishable difference in the maximal dose to the brainstem between the plans for normoxic
and hypoxic tumors. Also, in this case the plan with 16O has demonstrated an appreciable lowest
maximal doses to the target and residual tissue compared to the lighter ions in case of a hypoxic
tumor. For the other three cases of hypoxic tumors the plans with 16O perform very similar to
the ones with 12C.
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(a)
(b)
Figure 3.10.: Biologically optimized two-field plan for a partially hypoxic adenoid cystic carci-
noma, case A. (a) RBE- and OER-optimized biological dose distributions in axial,
coronal and sagittal planes. The solid white line marks the tumor, yellow lines
- brainstem (OAR) and eyes. The scale represents the relative dose received by
the tissue, compared to the prescribed biological dose of 2 Gy. The three isocen-
tric hypoxic regions with 0%, 0.15%, and 0.5% pO2 are marked with dotted white
lines. More detailed configuration of the hypoxic regions are given in Figure 3.2.
(b) DVHs for the target, brainstem and residual tissue (RT) for the plans with 16O
(red), 12C (blue), 4He (green), and 1H (black) for the cases of hypoxic (solid line)
and normoxic (dashed line) ACCs.
74 3. Treatment planning studies with oxygen beams
(a)
(b)
Figure 3.11.: Biologically optimized two-field plan for a partially hypoxic adenoid cystic carci-
noma, case B. (a) RBE- and OER-optimized biological dose distributions in axial,
coronal and sagittal planes. The solid white line marks the tumor, yellow line - the
brainstem. The scale represents the relative dose received by the tissue, compared
to the prescribed biological dose of 2 Gy. The isocentric hypoxic regions with 0%,
0.15%, and 0.5% pO2 are marked with dotted white lines. More detailed config-
uration of the hypoxic regions are given in Figure 3.2. (b) DVHs for the target,
brainstem and residual tissue (RT) for the plans with 16O (red), 12C (blue), 4He
(green), and 1H (black) for the cases of hypoxic (solid line) and normoxic (dashed
line) ACCs.
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(a) (b)
Figure 3.12.: Maximal relative dose received by the brainstem (a) and residual tissue (b) for the
plan optimized for a 2 Gy RBE- and OER-weighted dose for a normoxic (N) or par-
tially hypoxic (H) adenoid cystic carcinoma irradiated with 16O, 12C, 4He, or 1H.
The previous section with a model target aimed at estimating the damage to the residual
tissue and analyzing the potential benefit of oxygen ions only in the entrance channel of the
beam. As mentioned above, not for all the patient plans this information is of a high importance
when most of the organs at risk normally do not lie in the beam path. In the analyzed cases of
chordoma and ACC the most vital organs were avoided in the beam path. However, for some
tumors excluding of OAR or other important structures from the beam path is not possible and
the results of the model volume test mentioned above become relevant.
An example of such treatment plan containing the structures also in the beam entrance chan-
nel is the prostate cancer. To minimize the damage to the bladder and rectum, the fields are
usually selected in the way that the beams do not pass through them. However, this field con-
figuration makes the damage to the hip joints unavoidable. Two examples are given in Figures
3.13(a) (case A) and 3.14(a) (case B). There the geometries, contours of hypoxic regions, and
the RBE- and OER-weighted dose distributions in three orthogonal central CT planes are shown.
Despite the geometries looking very similar at a first glance, the tumor in case B is almost three
times smaller that in case A (52 cm3 compared to 149 cm3). It is also slightly more hypoxic (the
relative size of normally oxygenated area is 8% smaller than in case A). As can be seen from
the axial and coronal planes, for both plans the hip joints are placed exactly in the entrance
channels of each of the two beams, and one can expect them to receive a relatively high dose.
However, these doses are expected to be different due to the relative position of the hip joints
and the tumors. In case B, according to the coronal plane CT image, the geometrical centers
of the hip joints are located lower than the one of tumor. Thus, with a given field configura-
tion only few slices of the hip joint are expected to lay in the beam entrance channel, leading
to a reduction of the mean dose to the organ. The resulting DVHs for the target, rectum and
bladder data for cases A and B for normoxic and hypoxic targets for the prescribed RBE- and
OER-weighted target dose of 2 Gy are given in Figures 3.13(b) and 3.14(b), respectively.
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(a)
(b)
Figure 3.13.: (a) RBE- and OER-weighted dose distribution for the biologically optimized two-
field plan for a partially hypoxic prostate tumor, case A, in axial, sagittal and coro-
nal planes. The tumor is marked with a solid white line, the yellow contours below
and above mark the bladder and the rectum, respectively. The two yellow circles
on the right and on the left to the tumor outline the hip joints. The three isocentric
hypoxic regions in the tumor with 0%, 0.15% and 0.5%pO2 are marked with dashed
white lines. The scale represents the relative dose received by the tissue, compared
to the prescribed biological dose of 2 Gy. (b) DVHs for the treatment plan for 16O
(red), 12C (blue), 4He (green), and 1H (black) for normoxic (dashed line) and hy-
poxic (solid line) for a prescribed uniform RBE- and OER-weighted dose of 2 Gy.
The data is presented for the target, rectum (bold lines), and bladder (thin line).
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(a)
(b)
Figure 3.14.: (a) RBE- and OER-weighted dose distribution for the biologically optimized two-
field plan for a partially hypoxic prostate tumor, case B, in axial, sagittal and coronal
planes. The tumor is marked with a solid white line, the yellow contours below and
above mark the bladder and the rectum, respectively. The two yellow circles on
the right and on the left to the tumor outline the hip joints. The three isocentric
hypoxic regions in the tumor with 0%, 0.15% and 0.5%pO2 are marked with dashed
white lines. The scale represents the relative dose received by the tissue, compared
to the prescribed biological dose of 2 Gy. (b) DVHs for the treatment plan for
16O (red), 12C (blue), 4He (green), and 1H (black) for normoxic (dashed line) and
hypoxic (solid line) for a prescribed uniform RBE- and OER-weighted dose of 2 Gy.
The data is presented for the target, rectum (bold lines), and bladder (thin line).
3.3. Results and discussion 79
To avoid overloading the DVHs with information, the data for the hip joints was excluded
from them. Instead, the separate DVH for the left hip joint for case A is given below in Figure
3.15. For the case B the general trend is similar, and thus not given in order to not to overload
the chapter with figures. The corresponding numerical values of minimal, maximal, and mean
doses to the target and all the mentioned structures for both cases are provided in Tables 3.5.
The trend for the dose coverage of the target remains similar to the cases of the chordoma
and the ACC: the plan quality in the presence of hypoxia is least affected in case of heavier ions
such as 12C and 16O. As in the previous treatment plans, the standard deviation of the hypoxic
target dose coverage remains the lowest for 16O and is 0.05 Gy in case A and 0.06 Gy in case B.
The average dose to the rectum and bladder, which were selected for the analysis as the lateral
OARs, was not significantly varying between the two oxygenation cases as well. However, the
values of the mean doses to these structures vary significantly between the two cases. This can
be explained by the different geometries: in case A, there is a large overlap of the tumor with
rectum and bladder. Thus, large areas of these structures will receive the dose of an order of
the prescribed dose to the target. This leads to the mean doses of ≈0.6 and 0.4 Gy, respectively,
for the plans with the heavier ions. In contrast, for the case B this values are ≈0.2 and 0.06 Gy.
For both plans there is a very small difference in the mean doses to the OAR, delivered by 12C
and 16O. Moreover, in contrast to the plans for chordomas and ACC, this difference is in favor
of plans using 16O. However, to draw the final conclusions about the benefit of the latter ion,
at this step one should also consider the accuracy of the dose calculation of about 3%, as was
concluded from the dose measurements in the previous chapter.
Figure 3.15.: Dose-volume histogram for the treatment plan for 16O (red), 12C (blue), 4He
(green), and 1H (black) for normoxic (dashed line) and hypoxic (solid line) prostate
tumor for a prescribed uniform biological dose of 2 Gy. The data is presented for
the left hip joint laying in the beam path.
80 3. Treatment planning studies with oxygen beams
Io
n
VO
I
C
as
e
A
C
as
e
B
N
or
m
ox
ic
tu
m
or
H
yp
ox
ic
tu
m
or
N
or
m
ox
ic
tu
m
or
H
yp
ox
ic
tu
m
or
D
m
in
/
D
m
ax
/
D
m
ea
n
/
D
m
in
/
D
m
ax
/
D
m
ea
n
/
D
m
in
/
D
m
ax
/
D
m
ea
n
/
D
m
in
/
D
m
ax
/
D
m
ea
n
/
D
p
D
p
D
p
D
p
D
p
D
p
D
p
D
p
D
p
D
p
D
p
D
p
16
O
Ta
rg
et
0.
62
1.
05
0.
99
0.
59
1.
13
0.
99
0.
90
1.
05
0.
99
0.
89
1.
12
0.
99
R
ec
tu
m
0
1.
04
0.
30
0
1.
09
0.
30
0
1.
05
0.
09
0
1.
09
0.
09
B
la
dd
er
0
1.
05
0.
19
0
1.
07
0.
20
0
1.
04
0.
03
0
1.
04
0.
03
H
ip
Jo
in
t
0
0.
31
0.
16
0
0.
42
0.
19
0
0.
21
0.
06
0
0.
24
0.
06
R
es
id
ua
l
0
1.
11
0.
00
5
0
1.
2
0.
00
6
0
1.
09
0.
00
3
0
1.
12
0.
00
3
12
C
Ta
rg
et
0.
49
1.
08
1
0.
46
1.
17
1
0.
89
1.
05
1
0.
86
1.
16
0.
99
R
ec
tu
m
0
1.
05
0.
29
0
1.
12
0.
3
0
1.
05
0.
09
0
1.
11
0.
09
B
la
dd
er
0
1.
06
0.
21
0
1.
11
0.
21
0
1.
05
0.
03
0
1.
05
0.
03
H
ip
Jo
in
t
0
0.
26
0.
14
0
0.
42
0.
19
0
0.
19
0.
05
0
0.
24
0.
06
R
es
id
ua
l
0
1.
12
0.
00
5
0
1.
22
0.
00
6
0
1.
07
0.
00
2
0
1.
16
0.
00
3
4
H
e
Ta
rg
et
0.
60
1.
07
1
0.
59
1.
29
1
0.
86
1.
06
1
0.
79
1.
25
1
R
ec
tu
m
0
1.
05
0.
35
0
1.
18
0.
35
0
1.
04
0.
13
0
1.
14
0.
13
B
la
dd
er
0
1.
03
0.
28
0
1.
16
0.
27
0
1.
04
0.
05
0
1.
04
0.
05
H
ip
Jo
in
t
0
0.
28
0.
16
0
0.
49
0.
21
0
0.
19
0.
06
0
0.
30
0.
07
R
es
id
ua
l
0
1.
07
0.
00
6
0
1.
30
0.
00
7
0
1.
06
0.
00
3
0
1.
27
0.
00
3
1
H
Ta
rg
et
0.
74
1.
06
0.
99
0.
66
1.
53
0.
98
0.
85
1.
03
0.
99
0.
74
1.
41
0.
98
R
ec
tu
m
0
1.
04
0.
50
0
1.
23
0.
50
0
0.
99
0.
22
0
1.
15
0.
2
B
la
dd
er
0
0.
99
0.
47
0
1.
19
0.
41
0
1.
00
0.
09
0
1.
07
0.
10
H
ip
Jo
in
t
0.
01
0.
34
0.
24
0.
01
0.
77
0.
32
0
0.
29
0.
13
0
0.
40
0.
13
R
es
id
ua
l
0
1.
06
0.
00
9
0
1.
53
0.
01
0
0
1.
04
0.
00
5
0
1.
41
0.
00
5
Ta
bl
e
3.
5.
:M
in
im
al
(D
m
in
),
m
ax
im
al
(D
m
ax
)a
nd
av
er
ag
e
(D
m
ea
n
)r
el
at
iv
e
do
se
s,
co
m
pa
re
d
to
th
e
pl
an
ne
d
do
se
of
2
G
y(
RB
E,
O
ER
)(
D
p
),
in
ca
se
of
irr
ad
ia
tin
g
no
rm
ox
ic
or
pa
rt
ia
lly
hy
po
xi
c
pr
os
ta
te
tu
m
or
w
ith
16
O
,1
2
C,
4
H
e
an
d
1
H
io
ns
.
3.3. Results and discussion 81
The maximal doses received by these rectum and bladder remain the lowest in case of hypoxic
tumor when the 16O or 12C ions are used; the difference between these two ions is hard to dis-
tinguish within the potential dose calculation uncertainty. For example, in case A the difference
between 16O and 12C for the maximal doses is only 1.6% and 3% for the rectum and bladder,
respectively. Same trend is relevant for the maximal dose to residual tissue.
Regarding the impact of hypoxia on the dose delivered to the hip joints, a trend somehow
similar to the study shown in the previous section, can be distinguished. An example for the
case A is illustrated in Figure 3.15. While with normoxic tumors 4He, 12C and 16O deliver the
comparable low doses in the the entrance channel and thus perform similarly in terms of the
mean dose to the left hip joint (16, 14, and 16% from the prescribed dose of 2Gy, respectively),
the picture changes in presence of hypoxia. The difference in the dose between the different
ions is shifting the other way around (21, 19 and 19% for 4He, 12C, and 16O, respectively). The
effect can be easily noted in the Figure 3.15. Similar trend, but even more pronounced (Table
3.5) is also valid for the maximal dose. According to the tests in the previous section, one can
expect the further increase of the difference between the 12C and 16O with increasing size of
the hypoxic region. The study with the model target showed the largest effect when more than
80% of the tumor is hypoxic. In this case, however, it is less than 50% and, moreover, the
oxygenation is varying inside the region.
3.3.4 Summary
As can be generally concluded from this study, it is impossible to make a general selection
of the cases where one can benefit from using 16O ions instead of the lighter modalities. One
always has to account for the tissues radiosensitivity, geometry and field configuration to make
a proper choice of the ion. As can be seen from the analysis in normoxia for both the idealized
geometry and real tumor cases, the use of 16O for normoxic targets is not justified, since it
results in increased doses in the entrance channel and the doses to the OARs, both lateral and
those in the beam path.
As follows from the idealized geometry tests, the general argument in favor of considering
16O are the relatively low prescribed doses and the presence of large hypoxic parts in the tumor.
This can be beneficial in the moderate hypofractionated therapy, when the slightly higher doses
of 2.4-4 Gy are given per treatment fraction, in contrast to conventional fractionation with doses
of 1.8-2 Gy per fraction [Benjamin et al., 2017].
The high level of hypoxia is often the case for the real tumors, as the recent studies on tumor
oxygenation show. The review study of [Janssen et al., 2005] demonstrates that different visu-
alization methods prove the presence of hypoxia in a large number of head and neck cancers;
same refers to the prostate tumors [Marignol et al., 2008; Fraga et al., 2015; Rupp et al., 2016].
Another tumor proven to be significantly hypoxic is pancreatic cancer [Erickson et al., 2015;
Erkan et al., 2016]. Regarding the examples of numerical data, the study of [Cheney et al.,
2014a] investigated the chordoma of the mobile or sacrococcygeal spine patients and revealed
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the presence of hypoxic subvolumes of noticeable sizes (≥ 5 cm3 for regular-sized and ≥ 8 cm3
for the T2 stage tumors) in 60% of investigated patients. These data underline the relevance of
the studies presented here.
However, on the one hand, these studies were limited by the amount of patient data available
for calculations, but, on the other hand, they allow outlining another circle for oxygen beam
application limitations.
The first conclusion that can be drawn, based on all six analyzed patient cases, is that the main
benefit of treatment plans with 16O is mainly the resistance of the plan quality to the presence
of different levels of hypoxia. This is an essential argument in fractionated therapy since the
locations and sizes of hypoxic volumes are proven to vary between and during the subsequent
treatment sessions.
Regarding the mean dose to the lateral OARs, it remains somewhat intermediate, due to the
increased portion of fragmentation compared to 12C and reduced scattering, compared to 4He
ions. The best result in terms of the mean dose was demonstrated by 16O for both analyzed
cases of prostate tumor, where the mean dose was similar or even slightly lower than for 12C
plans.
Delivering the lowest possible maximal dose can be crucial in case of serial organs, such
as brainstem. The analysis of the maximal dose for all the hypoxic tumors has demonstrated
the decrease of this parameter with the increase of ion mass. The significance of the resulting
difference is expected to be dependent on the level of target location and oxygenation level. In
the analysis with chordoma tumors more pronounced benefit of 16O ions was observed for a
more hypoxic tumor.
The study with two cases of ACC did not show a significant difference between 16O and 12C.
The reason for a slightly better results achieved with 12C plans can be the field configuration
due to which the brainstem is located in the fragmentation tail of one of them. Additionally,
according to the analysis presented by [Inaniwa et al., 2017], use of orthogonal fields (which is
close to be the case for the analyzed ACC treatment plans) does not allow the most favorable
LET distribution inside the target.
Switching to the geometries with more deep-seated targets, such as the prostate cancer, fur-
ther smears the difference between 16O and 12C. The mean dose to the organs at risk becomes
similar for these two ions, while in terms of the maximal doses 16O might be still beneficial,
however the corresponding difference is only of order of few percent. This analysis shows that
for this particular case the only benefit from using the 16O fields is a slightly better target cover-
age (2.8% vs. 3.7% for 12C). This is far from being a striking argument in favor of 16O beams.
However, for the structures laying in the entrance channel one can expect the slight further
decrease of the dose with the further growth of hypoxia contribution, similarly to the effect
observed during the studies with idealized target. It should be additionally mentioned, that in
both the prostate and ACC cases analyses the respective tumors were significantly different in
sizes. However, all the analyzed effects remain similar. To further conclude whether there is a
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strong dependency of the doses received by OARs on the tumor size, more treatment planning
studies are needed.
Since the real PET data on hypoxia distribution is still not achievable with the needed ac-
curacy, this study remains an assumption. Apart from that, the treatment planning studies,
presented in this section, were partially limited by the capabilities of the tool to transfer the
realistic, measured hypoxia maps to the studied cases. Despite the modeled hypoxic regions
occupying the significant parts of the tumors slices to which they belong, the ratio of the total
size of the emulated hypoxic parts to the total volumes of the tumors was not very high. As
mentioned above, in reality the hypoxic regions may occupy a drastic central part of the tumor,
at the same time having a complicated internal pO2 distribution. Modeling a more realistic oxy-
genation distribution that shapes better to the tumor contours requires an updated tool. The
development of such tool together with the further tests is beyond the scope of the current work
and is left for the further research.
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4 Multiple ion treatment planning
involving oxygen beams
4.1 Introduction
The treatment planning study in the previous chapter revealed that in the idealized symmetric
geometry oxygen ions are the most advantageous in terms of sparing the healthy tissue in the
beam entrance channel when the tumor is highly hypoxic. To get the lowest dose to the residual
tissue and OAR with the same tumor dose coverage in normoxia carbon or helium ions remain
the optimal choice.
The idea of combining different ions to overcome hypoxia is demonstrated in Figure 4.1.
Figure 4.1.: The main idea behind using the multiple-ion treatment planning for overcoming tu-
mor hypoxia: reducing the dose to residual tissue by forwarding the high-LET heavier
ions to the hypoxic regions, while covering the remaining normoxic target parts with
lighter ions.
The hypoxic parts of the tumor can be irradiated with heavier ions with a higher LET depth
distribution: the high ionization density results in a lower OER values and therefore in an
increased total biological effect compared to the lighter ionic species. On the other hand, the
remaining dose in the normoxic regions can be covered by the lighter ions, which results in
less fragmentation and lower RBE values, thus allowing better protection of the surrounding
residual tissue and OAR. The simultaneous optimization of several ion fields, considering the
physical and radiobiological benefits and disadvantages of each modality, is expected to increase
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the quality and flexibility of treatment planning, and would allow exploiting the given ion fields
with the optimal plan beyond a pure empirical boost. As previously mentioned, despite several
ongoing studies of other groups, this approach specifically for hypoxic tumors was never realized
by anybody before.
The immediate rationale for applying a combined plan is the behavior of the single ions
in normoxic and hypoxic conditions. For example, if 4He ions deliver the higher dose to the
brainstem in case of the two-field irradiation of normoxic chordoma due to their increased
lateral scattering as compared to 16O, one should not expect a further improvement of the
treatment plan when the tumor hypoxia information added to the optimization. Thus, 16O will
remain the better choice for both cases and mixing it with a lighter ion beam will worsen the
quality of the plan.
4.2 Materials and methods
4.2.1 TRiP98-multiion-OER
To enable the multiple-ion optimization accounting for hypoxia with TRiP98, two current ad-
vanced versions of the TPS were merged. The current production version is capable of carrying
out the optimization with multiple-ion fields [Krämer et al., 2014]. The inclusion of hypoxia
effect into TRiP98-OER [Scifoni et al., 2013] was done in parallel to the implementation of the
multiple-ion species approach and at the moment of the beginning of the current study study
TRiP98-OER was able to handle only one ion modality per treatment plan.
Thus, the calculation algorithms related to the OER importing, handling and interpolation,
and biological dose calculations were transferred and partially expanded or improved from
TRiP98-OER to the production version. This implies:
• modifications of the biological effect calculation to include the OER;
• improvement of the calculation of the dose gradient, driving the optimization by including
OER as a driving force for the optimization;
• import of the pO2 data (the new method is explained in Appendix C; not part of the work
presented here).
4.2.2 RBE- and OER-weighted dose calculation
The difference in the biological dose calculation, compared to the algorithm used in [Scifoni
et al., 2013] is accounting for the mixed radiation field created by not only one, but several
primary ions for each raster spot and depth bin. In the recent version the additional summation
through all the primaries was introduced in the biological dose calculation step.
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For a set of primary particle beams traveling in water, the equation 1.2 for the absorbed dose
can be rewritten as
D(G y) = C × Fη(mm−2)× LET

MeV
g cm−2

(4.1)
where Fη is a particle fluence, C = 1.602189×108, and LET is the dose-averaged linear transfer
resulting from the contributions of all the primary beams, defined as in Equation 2.4.
According to the low-dose approximation, introduced in [Krämer and Scholz, 2006], the
biological response (cell survival) can be obtained as
− lnS =
¨
D (βD+α) , D ≤ Dcut
Dcut (βDcut +α) + (D− Dcut)Smax , D > Dcut (4.2)
where Dcut , Scut are the LQL parameters controlling in LEM the transition to exponential dose-
effect relation at high doses, and smax = 2β ·Dcut+α is the corresponding slope. In this equation,
α and β represent the dose-weighted averages for radiobiological coefficients for the mixed field
calculated based on the knowledge of αl and βl of each of the mixed field components.
Considering the effect of hypoxia by introducing the OER as a dose-modifying factor [Scifoni
et al., 2013; Tinganelli et al., 2015], i.e.
D′ = D
OER
, (4.3)
with the oxygen enhancement ratio OER defined as in equation 2.8, but considering the contri-
butions from all the primary beams in the dose-averaged LET calculation, the equation 4.2 for
the biological effect can be rewritten as
− ln(S) =

D
OER

β
D
OER
+α

, D ≤ Dcut
Dcut
OER

β
Dcut
OER
+α

+ (D− Dcut) · smax D > Dcut
(4.4)
and the biological dose can be calculated as
Dbio =
¨Æ− lnS / βX + (αX / 2βX )2 − (αX / 2βX ), D ≤ Dcut
(− lnS + lnScut) / Smax + Dcut D > Dcut
(4.5)
with αX and βX being the photon response parameters.
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The biological dose optimization in TRiP98 is usually done using gradient-based methods,
so when accounting for the OER effect, the gradients have to be be modified accordingly [Tin-
ganelli et al., 2015]:
∇α′  LET, pO2= ∇α
OER
 
LET, pO2,i
 −α∇OER LET, pO2
OER
2 (4.6)
∇Æβ ′  LET, pO2= ∇pβ
OER
 
LET, pO2
 −Æβ∇OER LET, pO2
OER
2 (4.7)
In the TRiP98-OER version the calculation of the second term was omitted as considered neg-
ligible. In the updated multiple-ion version the second term was added, with ∇OER calculated
based on its definition as in equation 2.8.
4.3 Results and discussion
4.3.1 Dose redistribution for unevenly oxygenated tumors
This subsection describes the basic test of the multi-ion optimization method for hypoxic
target. For this study, a geometry similar to the one used in the previous chapter in the study
with hypoxic tumors was emulated. A cubic water target volume of 40 × 40 × 60 mm was
placed in the center of a water CT cube of 200 × 200 × 160 mm (CT voxel size was chosen as 2
mm in x- and y-directions and the slice distance as 2 mm as well). The central target region of 28
mm (66 ≤ z < 94 mm) was chosen to have the oxygenation level of 0.5% pO2. The RBE tables
for the CHO cell line (Appendix A) were used for the biological optimization. The optimization
was performed for the two pairs of opposite fields (16O + 16O and 4He + 4He, couch angles
180 and -180 degrees for each pair of fields). The plan was optimized for a uniform RBE- and
OER-weighted dose of 6.5 Gy that would correspond to the target survival of 10% for the given
cell line. No additional constraints were applied. In total, 19 energies of 16O beams, varying
from 280.29 MeV/u to 188.27 MeV/u, and 19 energies of 4He beams, varying from 124.78 to
85.64 MeV/u, were used.
The results of the kill-painting optimization with multiple fields are presented in Figure 4.2.
Here, the central cuts of the dose and dose-averaged LET cubes in XZ plane are given, including
the resulting distributions and the dose contributions from each ion. 16O ions dominate in the
central hypoxic part while the contribution of 4He is more significant in the peripheral regions of
the target. From the 4.2(a) one can immediately note the difference in the lateral scattering of
the beams: the lateral dose fall-off caused by the higher portion of 16O beams to the central part
is lower than the lateral fall-off generated in the side areas of the target, where the contribution
of 4He ions is more significant.
For providing more quantitative information, the one-dimensional cuts from the survival, dose
and dose-averaged LET cubes along the central line are given in Figures 4.3. Figures 4.3a and
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Figure 4.2.: Results of the plan optimization with four opposite fields (16O+16O and 4He+4He for
a uniform survival of 10% in the target. The oxygenation distribution was modeled
as follows: for 66≤ z < 94 mm pO2 = 0.5% and 21% for the rest of the volume. (a) 2D
RBE- and OER- weighted total dose distribution in XZ plane, (b), (c) - contributions
of 16O and 4He fields, (d) 2D total absorbed dose distribution in XZ plane, (e), (f) -
contributions of 16O (b) and 4He fields, respectively, (g) - the resulting dose-averaged
LET distribution. The 100% of the color scale correspond to the dose value of 6.5 Gy
for Figures (a)-(f) and 60 keV/µm for (g).
4.3b demonstrate the resulting total survival in the target of 10% and the corresponding RBE-
and OER-weighted (6.5 Gy) and absorbed doses at the central line of the emulated geometry
along the beam direction. Similar to the single-ion plans, mentioned in the previous chapter,
the inhomogeneities arise due to the drastic decrease in oxygenation between the neighboring
voxels; however, these fluctuations do not exceed the values of 9.5% of the absolute values, and
the overall quality of optimization is acceptable.
The separate contributions of each ion to the physical and biological doses are shown in
Figures 4.3(c) and 4.3(d), respectively. As can be seen from Figure 4.3(c), in the normoxic part
of the target the contribution of 4He is more significant than for 16O (up to ≈ 3.25 Gy compared
to ≈ 2.5 Gy), while in the central hypoxic part the preference is given to 16O (≈ 4 Gy compared
to ≈ 3.25 Gy).
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a) b)
c) d)
e) f)
Figure 4.3.: Results of the plan optimization with four opposite fields (16O+16O and 4He+4He)
for a uniform target survival of 10%. The oxygenation distribution was modeled as
follows: for 66 ≤ z < 94 mm pO2 = 0.5% and 21% for the rest of the volume. The
profiles are extracted from the corresponding calculated cubes at the central lines (x
= 100, y = 100) along z direction. (a) Total cell survival. (b) Total absorbed (dotted
line) and RBE-weighted (solid line) dose profiles. (c) Absorbed dose contributions
from pairs of fields: red - 16O+16O, blue - 4He+4He. (d) RBE- and OER-weighted
contributions from pairs of fields: red - 16O+16O, blue - 4He+4He. (e) Dose-averaged
LET profile in comparison with similar plans optimized for two opposite fields either
of 16O (dashed red line) or 4He (dashed blue line). (f) Corresponding comparison of
OER distributions calculated according to the model approach of [Tinganelli et al.,
2015]. For all the figures the target area is marked with crosses.
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This will result in a well-pronounced 16O boost in the biological dose to the hypoxic region (Fig-
ure 4.3d), while the contributions to the dose distribution in the normoxic parts will become
almost equal with a slight preference given to 4He ions. This optimization yields a dose-averaged
LET profile shown in Figure 4.3e. Here, an additional comparison with the dose-averaged LET
profiles of the single-ion 16O and 4He plans is given. As can be seen, the multiple-ion opti-
mization allows one to noticeably increase the LET up to 60-75 keV/µm in the hypoxic part,
compared to the planning performed only with light ions (4He) where the LET distribution is
almost uniform and does not exceed 15 keV/µm. At the same time, the unnecessarily high LET
in the normoxic regions is avoided, compared to the 16O plan. Thus, the combined plan allows
achieving the LET distribution better shaped to the oxygenation distribution.
As can be seen from the Figure 4.3f, the corresponding OER values in the central hypoxic
part are 1.55, 1.28 and 1.45 for 16O, 4He and their combination, respectively. In contrast to the
slightly rounded OER distribution for the 16O and combined plans, the OER distribution for the
4He beams plan has a rectangular shape. This means that the OER values in this region reach
their maximum predicted by the model for this particular level of oxygenation and no reduction
in the dose due to the LET effect occurs at all. Here one should keep in mind, that in the model
of [Scifoni et al., 2013; Tinganelli et al., 2015] the OER-LET dependency on the particle type
was not discussed, but found negligible. The model study proposed by [Strigari et al., 2017]
demonstrated that for the lighter particles such as 4He the OER decrease might occur at the
lower LET values; thus, updating of the current OER look-up tables in TRiP98 according to their
model might slightly affect the shape of the OER-z distribution. However, this study is beyond
the scope of the presented work.
When no constraints except the prescribed target dose for the planning are imposed, the opti-
mization aims only at achieving the desired uniform dose distribution in the target. Thus, when
no additional driving forces in the optimization and no planning constraints are introduced, the
system is expected to calculate the plan giving similar preferences to each primary beam that is
included. No actual field redistribution occurs, but the delivered dose is instead split between
the beams. Thus, as mentioned before, it might worsen the dose distribution in residual tissues
or organ at risk, if one of the included ions performs noticeably better than the other. However,
if the geometry is more complex and implies organs at risk or just the irregular target shape, dif-
ferent ions might perform differently in neighboring target regions, the quality of the combined
plan might be better compared to the corresponding single-ion plans.
4.3.2 Comparison with single-ion optimized plans
The patient study presented in this section aims at the comparison of the planning performed
with the combination of 16O with 4He with their corresponding single-ion plans. For this study,
a medium-sized skull base chordoma with the volume of ≈ 133 cm3 was chosen. In contrast
to the chordoma plan analyzed in the previous chapter, for this case, the tumor is slightly more
wrapped around the brainstem. The field configuration, preserved from the original plan (couch
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angles were set to 100 and -100 degrees) makes the brainstem lay partially in the fragmentation
tail of one of the two almost opposite fields. For the treatment planning tests, the values of
FWHM were selected as 5 mm for 16O beams and 7 mm for 4He beams. The distance between
the subsequent peak positions was kept 3 mm for all the fields in all plans. The raster scanner
steps in x- and y-directions were set to 2 mm for the 16O plans, 3 mm for the 4He plans and 4 mm
for each ion field in the combined plans. The OAR constraint was transferred from the original
plan, where the maximal dose fraction for the spinal cord was set to 0.55 with a weighting factor
of 0.8. Apart from that, there were no differences in other plans parameters and optimization
algorithms, compared to the patients’ study from the previous chapter.
4.3.2.1 Normoxic target
The central axial, coronal and sagittal planes of the resulting RBE-weighted dose cube for
the two-fields 16O plan optimized for a normally oxygenated skull base chordoma are given in
Figure 4.4.
Figure 4.4.: Biologically optimized two-field 16O plan for a normally oxygenated skull base cror-
doma. The three corresponding orthogonal central CT cuts are are shown. The
tumor is marked with a solid white line, the inner yellow line outlines the brainstem,
the outer yellow line - the contour of the patient’s head. The color scale represents
the relative dose received by the tissue, compared to the prescribed RBE-weighted
dose of 2 Gy.
The dose cube cuts for the 4He plan are not presented here since the visual difference is not
significant between them and the ones for the 16O plan on this scale. However, it is important
to note that from the geometry of the tumor it follows that in case of the 16O plan, one part of
the brainstem receives a noticeably higher dose compared to the 4He plan due to the significant
portion of fragmentation. However, in case of 4He, another part of the brainstem might be at
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risk when the higher doses are applied, due to the scattering of the beam coming from another
direction.
For the same target, the multiple-ion optimization was performed with two pairs of 16O and
4He ion fields coming from the same angles. The resulting total RBE-weighted and physical
dose distributions at the axial plane together with the corresponding contributions from each of
the ions are given in Figure 4.5. Both 16O and 4He deliver the RBE-weighted dose of ≈1.2 Gy
(60% from the prescribed dose), which corresponds to the physical doses of ≈0.2 and ≈0.4 Gy,
accordingly, resulting in a uniform total RBE-weighted dose of 2 Gy in the target. This result is
consistent with the multiple ion tests with a C-shaped target ’wrapping’ the OAR demonstrated
by [Krämer et al., 2014], where the partial doses contributions from each ion inside the target
were similar.
Figure 4.5.: Biologically optimized four-field 16O+4He plan. The chordoma and brainstem are
marked with white and yellow lines, respectively. The scale represents the relative
dose received by the tissue, compared to the prescribed RBE-weighted dose of 2 Gy.
(a) - total RBE-weighted dose, (b) and (c) - 16O and 4He contributions, (d) - total
absorbed dose, (e) and (f) - 16O and 4He contributions.
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The zoom-in of the dose distribution in the brainstem for two single-ion plans of 16O (Figure
4.4), 4He and the multi-ion plan (Figure 4.5) are given in Figures 4.6(a), (b), and (c), respec-
tively. One can notice that applying the mixed modality field leads to the decrease of the dose
received by the brainstem compared to the pure 16O plan: the ratio of the ’red’ high dose areas to
the ’green’ and ’blue’ low dose areas becomes less due to the ’dilution’ of one field with another.
Thus, the fragmentation in the upper part of the brainstem is reduced by partial irradiation with
4He field, while the potential effect of scattering in the lower part might be decreased by the
presence of 16O ions.
(a) (b) (c)
Figure 4.6.: RBE-weighted dose distribution at the central CT cut inside the brainstem (yellow
contour) for the (a) 16O plan, (b) 4He plan, and (c) combined four-field 16O + 4He
plan. The color scale is the same as in Figure 4.5.
The outcome of the three tests is summarized in Figure 4.7 showing the DVHs for the target,
brainstem and residual tissue for each of the three plans. The corresponding numerical values of
the minimal, maximal and mean relative doses received by the target, brainstem, and residual
tissue are given in Table 4.1. According to the DVH, the dose coverage of the target is similar
for all the three plans. Despite the differences in the minimal and maximal doses to the target,
the standard deviation of mean dose values is less than 2% (not given in the Table). This means
that only a few voxels out of the total tumor volume would receive the decreased or increased
dose; thus, this difference between the plans is not sufficient. At the same time, as can be seen
from the values presented in Table 4.1, applying the mixed field leads to the reduction of the
mean dose to the brainstem by 4.9% and by 12.7% compared to the single-ion 4He and 16O
plans, respectively. The dose to the residual tissue is generally very low since for its calculation
all the CT voxels are taken into account; however, it is also reduced by 4.3% compared to both
single-ion plans. The maximal doses to the brainstem and residual tissue remain intermediate.
Applying the combined field reduces the maximal dose to the brainstem by 2.6% compared to
the plan with 16O ions, but worsens it for 2% compared to the 4He plan. Regarding the residual
tissue, the maximal dose is reduced for 11.6% compared to the 16O plan and is 3.7% higher
compared to the plan optimized for 4He ions. These ’negative’ differences in the maximal doses
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are both less than 5% and are lower than in another case of chordoma, analyzed in the previous
chapter; however, the decrease of the mean dose to the brainstem is noticeable.
Figure 4.7.: Dose-volume histogram comparison for the two-fields plans of 16O (red), 4He
(green) and a four-field combined plan 16O + 4He (light blue), optimized for a uni-
form RBE-weighted dose of 2 Gy in a normally oxygenated skull base chordoma.
Solid lines correspond to the DVHs for the target, dashed lines - for the brainstem,
dot-dashed - for the residual tissue.
Ion type VOI Dmin/Dp Dmax/Dp Dmean/Dp
16O
Target 0.81 1.15 1
Brainstem 0 1.10 0.36
Residual 0 1.29 0.014
4He
Target 0.69 1.10 1.01
Brainstem 0 1.07 0.33
Residual 0 1.10 0.014
16O + 4He
Target 0.58 1.12 1.01
Brainstem 0 1.07 0.31
Residual 0 1.14 0.013
Table 4.1.: Minimal (Dmin), maximal (Dmax) and average (Dmean) relative doses, compared to the
planned target dose of 2 Gy(RBE) (Dp), received by the target, brainstem and residual
tissue in case of irradiating the normally oxygenated skull base chordoma with two
fields of 16O, 4He, or their four-field combination.
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4.3.2.2 Hypoxic target
For the estimation of the impact of the location and/or the size of the hypoxic area on the
quality of the multi-ion plan, two tests assuming the different oxygenation distributions inside
the target were carried out.
For the first test, one relatively small localized ellipsoid hypoxic region, occupying about 11%
of the total target volume, was emulated, as shown in Figure 4.8(a), where the CT slice 58 out
of 114 is demonstrated. In total, four oxygenation levels, concentrically decreasing in spherical
shells, were modeled inside the target: 21%, 0.5%, 0.15%, and 0% pO2. For the second test, a
noticeably larger (approximately 31% of the target) and a more extended region was emulated.
In this case, the target also had in total four levels of oxygenation. Figures 4.8(b) and 4.8(c)
demonstrate the corresponding pO2 distributions at the CT slices 56 and 59 out of 114. For each
test, the total sizes of each oxygenation region and their ratios to the total target volume are
summarized in Table 4.2.
(a) (b) (c)
Figure 4.8.: Emulated hypoxia distributions for the tests with skull base chordoma. The outer
yellow line corresponds to patient’s head contour, the inner yellow lines marks the
brainstem, and the white line marks the tumor contour. (a) First test - a relatively
small ellipsoid region with three levels of oxygenation: 0%, 0.15% and 0.5% pO2.
Slice 58 out of 114 is shown. (b), (c) Second test - a larger spread region with three
levels of oxygenation: 0%, 0.15% and 0.5% pO2. Slices 56 and 59 out of 114 are
shown, respectively.
The results of the multi-ion optimization for each of the two cases of target oxygenation
(further denoted as scenario 1 and scenario 2, respectively) are given in Figures 4.9 and 4.10,
respectively. Together with the total RBE- and OER-weighted and absorbed dose distributions
at the central CT slice, the corresponding contributions of each ion are given. In both cases of
oxygenation, the optimization does not worsen the uniformity of the RBE- and OER-weighted
dose distributions in the target (Figures 4.9(a) and 4.10(a)) compared to the single-ion plans.
The mean dose to the target remains 2 Gy with a standard deviation of 2.9% and 4.1% for
scenarios 1 and 2, respectively, while the deviations for the 16O plans are 2% and 2.8%, and for
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Table 4.2.: Parameters of the hypoxia maps generated for the multi-ion tests. Total volume
stands for the total volume of the target. The sum volumes of equally oxygenated
tumor subvolumes and their ratio to the total tumor volume are given in the last two
columns.
Test Total volume, cm3 pO2. % Volume, cm
3 % of the total volume
1 133.33 0 3.49 2.6
0.15 5.03 3.8
0.5 6.53 4.9
21 118.27 88.7
2 133.33 0 7.55 5.7
0.15 14.76 11.1
0.5 19.40 14.6
21 91.61 68.6
4He plans are 3.6% and 5.4%, respectively. The small inhomogeneities in the tumor coverage
are the results of the drastic pO2 changes and should be not the case for the treatment plans
with realistic hypoxia maps, where pO2 distribution is expected to be smoother.
For both scenarios, the trend in the biological dose delivered by different primaries is similar
to the test with the idealized geometry. The 16O ions dominate in the hypoxic parts of the
tumor (Figures 4.9(b) and 4.10(b)) by delivering the RBE- and OER-weighted dose boosts in
the rage of 1.8-2 Gy depending on the position inside the hypoxic region. At the same time,
the contribution from 4He fields is almost negligible there (Figures 4.9(c) and 4.10(c)). As can
be seen from the partial contributions to the absorbed dose, the dose distributions produced by
4He fields (Figures 4.9(f) and 4.10(f)) resemble the 4He contribution to the normoxic multi-ion
plan (Figure 4.5(f)) and are relatively uniform. Delivered to the hypoxic areas, such doses will
lead to the cell ’underkill’ depending on the level of OER, similar to the one shown in Figure
3.5. In contrast, the contributions of 16O fields in both scenarios demonstrate the pronounced
boost up to ≈0.5 Gy in the absorbed dose in the hypoxic areas (Figures 4.9(e) and 4.10(e), that
will compensate the absence of the ’helium dose.’ Thus, the TPS is ’excluding’ the lighter ion (in
this study, 4He) and performs the kill-painting optimization with a heavier modality to achieve
the higher LET and, consequently, lower OER values in hypoxic regions.
The dose-averaged LET distributions at the central CT slices for each of the two scenarios in
hypoxia are given in Figures 4.11(a) and (b), respectively. As can be seen from both figures, the
highest LET values up to 75 keV/µm are reached in the hypoxic regions, while the remaining
values do not exceed 40 keV/µm. As follows from Figure 1.10, achieving this level of LET
distribution will lead to the 1.3-, 1.2-, and 1.13-fold reduction of OER values in the regions with
pO2 = 0%, 0.15%, and 0.5%, respectively. There are few more regions, apart from the hypoxic
areas, mainly in the tops of the cuts, where the LET exceeds its average values.
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Figure 4.9.: Biologically optimized four-field 16O + 4He plan for a partially hypoxic skull base
chordoma (scenario 1). The tumor and brainstem are marked with white and yellow
lines, respectively. The scale represents the relative dose received by the tissue, com-
pared to the prescribed biological dose of 2 Gy. (a) - total biological dose, (b) and
(c) - contributions of 16O and 4He, (d) - total physical dose, (e) and (f) - contributions
of 16O and 4He.
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Figure 4.10.: Biologically optimized four-field 16O + 4He plan for a partially hypoxic skull base
chordoma (scenario 2). The tumor and brainstem are marked with white and yel-
low lines, respectively. The scale represents the relative dose received by the tissue,
compared to the prescribed biological dose of 2 Gy. (a) - total biological dose,
(b) and (c) - contributions of 16O and 4He, (d) - total physical dose, (e) and (f) -
contributions of 16O and 4He.
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One of the possible explanations to this effect can the presence of the few high-LET particles
in the distal regions delivering the very low doses. This will lead to the high values of the
dose-averaged LET in these regions. The similar effect was observed in the work of [Bassler
et al., 2014] presenting the results of the LET-painting optimization. However, in contrast to the
LET-painting, the kill- painting, achieve automatically an optimal LET distribution in the target,
without imposing a set of dose ramps, now demonstrated also in a 3D profile.
More information on the optimization results is given below. Figures 4.12 and 4.13 represent
the dose-volume histograms for the single-ion and combined plans for each of the two tests,
respectively. The following Table 4.3 contains the corresponding numerical values of minimal,
maximal and average relative doses received by the target, brainstem and residual tissue. The
final comparison of the mean and maximal relative doses delivered to the brainstem and residual
tissue between the hypoxic plans and normoxic plan is given in Figure 4.14.
As follows from the Tables 4.1 and 4.3, for all of the plans the mean doses delivered to the
brainstem are practically not affected by the presence of hypoxia, similarly to as what was shown
in the Chapter 3. For both cases of oxygenation the combined plan shows the lowest value of
this parameter, decreasing the dose by 10-12% compared to the pure 16O plan and 3-5% - to the
Figure 4.11.: Dose-averaged LET distribution at the central axial CT slice for the two biologically
optimized four-field 16O + 4He plans for a partially hypoxic skull base chordoma.
The tumor and brainstem are marked with green and yellow lines, accordingly.
The 100% on the scale corresponds to the dose-mean LET of 60 keV/µm. (a) - test
1, one small hypoxic region, (b) - test 2, a larger extended hypoxic region.
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Figure 4.12.: Dose-volume histogram comparison for the two-fields plans of 16O (red), 4He
(green) and a four-field combined plan 16O + 4He (light blue), optimized for a
uniform OER- and RBE-weighted dose of 2 Gy in a partially normoxic skull base
chordoma, scenario 1. Solid lines correspond to the DVHs for the target, dashed
lines - for the brainstem, dot-dashed - for the residual tissue.
Figure 4.13.: Dose-volume histogram comparison for the two-fields plans of 16O (red), 4He
(green) and a four-field combined plan 16O + 4He (light blue), optimized for a
uniform OER- and RBE-weighted dose of 2 Gy in a partially normoxic skull base
chordoma, scenario 2. Solid lines correspond to the DVHs for the target, dashed
lines - for the brainstem, dot-dashed - for the residual tissue.
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plan with 4He beams. For the second scenario with a larger hypoxic area this dose decrease in
case of the combined plan is slightly lower (≈10.7% and 3.1% compared to the single-ion plans).
The explanation might be the larger presence of 16O in the tumor regions in the proximity of
brainstem, which leads to a larger production of secondary particles, compared to the cases with
normoxic or another hypoxic target.
Similar to as in the tests presented in the previous chapter, the values of the maximal doses to
the brainstem are sensitive to the oxygenation level of the tumor and also depend on its location.
In particular, for the first scenario these values are almost not affected compared to the normoxic
plan since the field redistribution difference between these two plans (oxygen boost in hypoxic
region) occur in the area of the target laying relatively far away from the brainstem, while in the
remaining parts of the target the biological dose contributions are almost equal. The maximal
dose values remain approximately 2.21, 2.15 and 2.15 Gy for the 16O, 4He and the combined
plan, respectively. In the second scenario an increase in the maximal dose compared to the
normoxic plan is observed for all the three plans and is the most significant for the 4He (21%).
The most insensitive is the 16O plan (an increase of 5%). The relative increase for the combined
plan is intermediate (7.8%), however, the value it is reaching (2.15 Gy) is the same as the value
for the 16O plan.
Thus, for both scenarios, the combined plan tend to show the values similar to the better
single-ion plan out of two for the maximal dose to the brainstem. This way, in normoxic case
or for the targets with the small and deeply located hypoxic areas (scenario 1), the 16O + 4He
plan leads to the same maximal doses as the pure 4He plan, while with the spreading hypoxia
(scenario 2) the corresponding result will become similar to the one with 16O plan.
Ion type VOI
Test 1 Test 2
Dmin/Dp Dmax/Dp Dmean/Dp Dmin/Dp Dmax/Dp Dmean/Dp
16O
Target 0.81 1.16 1 0.79 1.17 1
Brainstem 0 1.10 0.35 0 1.16 0.35
Residual 0 1.27 0.014 0 1.23 0.014
4He
Target 0.68 1.31 1 0.67 1.31 1
Brainstem 0 1.08 0.33 0 1.30 0.32
Residual 0 1.31 0.014 0 1.37 0.015
16O + 4He
Target 0.58 1.23 1.01 0.57 1.23 1
Brainstem 0 1.08 0.31 0 1.16 0.31
Residual 0 1.23 0.013 0.001 1.27 0.014
Table 4.3.: Minimal (Dmin), maximal (Dmax) and average (Dmean) relative doses, compared to the
planned dose of 2 Gy(RBE,OER) (Dp), received by the target, brainstem and residual
tissue in case of irradiating two cases of partially hypoxic skull base chordoma with
two fields of 16O, 4He, and their four-field combination.
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With regards to the doses received by residual tissue, making the analysis based on the mean
dose values from the Table 4.3 is difficult since, as was previously mentioned, the main part of
the total number of CT voxels receive zero dose, making the mean value very low. The highest
mean dose among all the 9 examined plans (0.029 Gy) was observed for the 4He plan for the
most hypoxic tumor. It can be still mentioned that for both cases of hypoxia distribution the
value of the mean dose to the residual tissue is the lowest for the combined plan. However, the
trend for the maximal dose appears to be dependent again on the location and/or position of
the hypoxic region. For the scenario 1, the combined plan shows the best result too, providing
the decrease of the maximal dose to residual tissue by 3.2% compared to the 16O plan and 6.3%
- to the pure 4He plan. In scenario 2, adding the 4He beams to the pure 16O plan would, in
contrast, increase the maximal dose to residual tissue by 3.2%.
(a) (b)
(c) (d)
Figure 4.14.: Mean and maximal relative doses received by the brainstem (a, b) and residual
tissue (c, d) for the plan optimized for a 2 Gy RBE- and OER-weighted dose for a
normoxic (N) and two cases of partially hypoxic (H, T1 and T2) skull base chordoma
irradiated with two fields of 16O, 4He, and their four-field combination.
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4.3.3 Summary
The multi-ion optimization approach, presented here, allows performing the biological treat-
ment planning with several ion modalities simultaneously. When no particular constraints are
introduced, the contributions of each ion to the resulting biological dose are expected to be
almost equal. On the other hand, when hypoxia is used as a driving force for the optimization,
a redistribution of the fields occurs. The system forwards the heavier ions to the areas with
decreased oxygenation, while the lighter modalities are avoided there. The residual normoxic
areas receive the dose from both types of ions, with the slight preference given to the lighter
ones.
The tests, demonstrated in this chapter, aimed at the improvement of the quality of hypoxic
treatment plans with 16O beams with 4He ions chosen as a lighter alternative. The investigated
geometry was chosen in a way that in normoxic conditions the brainstem was receiving the
increased dose in case of the 16O plan. At the same time, the studies in the previous chapter
showed that the plans with 16O are the most ’insensitive’ to the presence of hypoxia, while 4He
performs noticeably worse in the same conditions. Applying the combined plan to the normoxic
target demonstrated the decrease of the mean doses to the brainstem and residual tissues while
keeping the corresponding maximal doses intermediate. When the multi-ion plan is applied to
the hypoxic targets, the difference in the mean doses might slightly decrease depending on the
size and location of hypoxic area, however, the maximal doses remain at the same levels as in
case of pure 16O plans. The study in the previous chapter demonstrated that 16O plans might
allow achieving the lowest maximal doses to the neighboring OARs when the hypoxic tumor is
irradiated. Thus, the multi-ion optimization, used with the hypoxic targets, allows both to keep
the maximal dose to the critical structures the lowest, while reducing the mean doses to them
and the residual tissue by optimally operating with the benefits of each of the ion.
As mentioned in the beginning of this chapter, the decision whether multi-ion optimization is
beneficial or not for the particular case of tumor, must be made based on the knowledge about
the performance of the corresponding single-ion plans. If the heavy ion plan allows achieving
the lower doses to OARs and residual tissue when applied to the normoxic target, it is expected
to show also the best performance in hypoxia.
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Summary and conclusion
In the past few years 16O ions started to gain the attention of researchers and clinicians in
the field of radiation therapy as an alternative to the already established 12C ion beam. The
main reason for that is the increased LET of the beam which was proven to be the key to
overcome the problem of tumor hypoxia. However, the increased atomic number of the ion
leads to several drawbacks as well. Among them are the increased nuclear fragmentation and
potentially unnecessarily high RBE. Thus, an in-depth study of physical and radiobiological
characteristics of the beam and further comparative treatment planning studies are essential to
asses the beam’s applicability for the clinical practice.
In this dissertation, the experimental verification of the clinically relevant physical and ra-
diobiological properties of 16O beams together with the following treatment plan analysis was
carried out. The GSI in-house TPS TRiP98 was expanded in order to enable the optimization
with multiple ion fields for hypoxic tumors and was tested with combined 16O and 4He plans.
The aim of the whole study was assessing the quality of the current status of the 16O beam
description and defining the ranges of its potential clinical application.
The experiments, presented in Chapter 2, have demonstrated the reliability of the currently
implemented physical beam model for 16O beams. The water phantom measurements with pin-
point chambers demonstrated a good agreement with the TRiP98 prediction for the absorbed
dose profiles in both beam eye view and lateral directions at different depths. The slight devia-
tion between the measurements and the TPS calculation in the lateral profile in fragmentation
tail region point the need for the further experimental investigation of 16O beams fragmen-
tation. At the moment, no experimental works on 16O fragmentation are published and the
TRiP98 beam model in based on the fragmentation data for the underlying ions.
The series of RBE measurements with the CHO-K1 cell line, triggered by the incomplete
knowledge of radiobiological properties of 16O ions, noticeably expanded the RBE-LET database
of the beams for both low and high LET values. It was shown that 16O RBE10 values for the
low (below 25 keV/µm) or very high (above 600 keV/µm) LET values are almost equal to the
photon efficiency, and reaches their maximum of≥2.5 in the region of 200-300 keV/µm. A more
precise estimation of the maximum values was not possible within the current work since the
beams of the required energies are not available at HIT and GSI facilities. More measurements
at 16O with energies in the range of 20-100 MeV/u are already planned at other facilities.
Since the main idea behind the introduction of 16O into clinical practice is the treatment of
hypoxic tumors, the corresponding radiobiological experiments were performed. The survival
measurements with GSI hypoxic chambers confirmed the TRiP98 predictions of the OER of 16O
beams with dose-averaged LET of 166 keV/µm. As a next step, the survival verification for the
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unevenly oxygenated extended target using the ’hypoxic phantom’ showed the applicability of
the kill-painting approach, developed earlier at GSI, to the ions beyond 12C. It was experimen-
tally demonstrated for the first time, that 16O might be more beneficial compared to the lighter
ion beams regarding the cell survival in the entrance channel when irradiating hypoxic tumors.
All the cell survival experiments in Chapter 2 were conducted with the cell monolayers. Apart
from potential differences between the cell growth and radiosensitivities when cultured in
monolayers and 3D, the latter way of the cell culture opens more opportunities for the more
sophisticated tests. For example, the resolution of the experiments could be increased and al-
low also the check of the cell survival in the lateral fall-off of the beam, or arranging the more
complicated phantoms for more realistic verifications.
Treatment planning studies, demonstrated in Chapter 3, aimed at comparison of quality of
optimization with 16O beams and lighter modalities, such as 12C, 4He and protons for normoxic
and hypoxic tumors. It implied the study for a box-shaped geometry used for the experiments
with extended target irradiation, as well as the studies with GSI pilot project patients plans and
artificially created complementary hypoxia maps. The study with the box target was inspired by
the experimental results obtained with the extended target irradiation and implied the analysis
of the survival in the entrance channel with the different impact of target hypoxia. The result
can be summarized as follows: for the treatment of the normoxic (21% pO2) or slightly hypoxic
tumors (≈ 20% or less of its volume has decreased pO2) with high doses the irradiation with
16O doses do not lead to any improvement of cell survival in the entrance channel. In contrast,
for the highly hypoxic tumors (>50% of the total volume has pO2 ≈ 0.5% or lower) irradiation
with 16O is expected to lead to 10-15% survival increase in the entrance channel in a single
fraction, compared to the lighter beams.
The following studies implying real patients plans assessed the tumor dose coverage and the
damage to the OAR in its proximity. It was demonstrated, that the treatment plans with 16O
beams are least sensitive to the presence of hypoxic regions in the target, which is essential
since the location and sizes of these regions can vary between the different treatment sessions.
Apart from that, 16O might deliver the lowest maximal doses to the OAR and residual tissue
when the tumor is higly hypoxic. This is an important benefit when it comes to the damage
of serial organs at risk. However, at the same time, 12C or 4He ions might still deliver the
lower average doses to the OAR and residual tissue. Thus, the decision on the type of ion to
be applied for the treatment of a particular tumor must always be based on its shape, level of
hypoxia, relative position of the OAR and their type (serial or parallel).
Chapter 4 introduced the latest version of the GSI TRiP98 TPS which is so far the only TPS able
to calculate the biological effect of several primary ions within one treatment plan for hypoxic
tumors. The aim of this approach is taking benefit from several ions inside one treatment plan,
such as the reduced nuclear fragmentation of the light ions or the high RBE and LET of the
heavier ions. Uniform cell survival is achieved by forwarding the heavier ion modalities to the
hypoxic regions of the target while covering the normoxic areas also with the lighter ions. This
allows one to increase the dose-averaged LET distribution in hypoxic parts to reduce the OER
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while avoiding the too high LET where it is not necessary. However, multiple-ion planning
has to be chosen wisely, since, apart from the generally longer optimization times and slightly
increased irradiation times, they can be worse than single-ion plans. In this chapter, the results
of testing this approach are given for combined 16O + 4He plans since both are mostly discussed
nowadays as the alternatives to the well-established 12C and 1H, respectively. In the study
with the skull-base chordoma, it was shown that applying a four-field combined plan allows
reducing the mean dose to the brainstem by 3-5% compared to the pure 4He plan and by 10-
12% compared to the pure 16O plan. At the same time this plan is beneficial regarding the
maximal dose to the OAR, since it always remains as low as possible, meaning it being the same
as for the 4He plan in normoxia and as for 16O plan in hypoxia.
As already mentioned, the studies with the patients’ plans presented in Chapters 3 and 4
were carried out with artificially created hypoxia maps. The tool that was used for generating
them implies a set of limitations on the sizes and locations of hypoxic regions. In all the studies
presented in this work, the hypoxic region was modeled as a rather regular-shaped area with
the oxygenation decreasing towards its center. Even if similar images of real hypoxia maps can
be found in literature, such as the ones for a head and neck squamous-cell carcinoma [Bassler
et al., 2014] or for a renal cell carcinoma [Fleming et al., 2015], a more random distribution
of smaller regions of more irregular shapes, varying in time, is expected to be found in many
tumors. Future realistic tests should use real hypoxia maps obtained from the clinics. At the
moment the problem of interpretation of FMISO-PET data remains not completely solved.
Another remaining task is performing the further multiple-ion studies involving other ions
apart from 16O and 4He, primarily 12C ions. As the study with the ACC patient plans in Chapter
3 revealed, 12C might remain beneficial even when applied to hypoxic tumors.
The experimental biological verification of the multiple-ion treatment planning is essential
and is one of the directions of the further work. Apart from the general estimation of the
planning reliability, it is important to make sure the increased time of the irradiation session
does not reflect the cellular effects. Another issue that is of a high importance for the combined
planning, is the precision of the particle range determination. Since the redistribution of the
fields is expected to occur in the different regions of the tumor, the positioning of the patient
and the calculations of the ranges of all the primaries have to be done with a high degree of
accuracy. However, this is not within the scope of the current work.
In general, the clinical application of the multi-ion approach is realistic. For example, at HIT
the switching from one ion type to another one coming from the same source (from 16O to 12C,
or vice versa) already takes not more than 10 minutes. Moreover, since the approach implies
the usage of different ion combinations, e.g., 16O + 4He, no switch is required at all since there
are different sources for these ions which run continuously. Recently, [Toshiba, 2017] reported
that they managed to achieve the switching time between the two ions within one source to
be less than a minute. Since the dose is split between more fields, the irradiation with each
of them will be shorter. This way, the total irradiation time is expected to exceed the one in
case of standard single-ion treatment only by the time required to rotate the patient. For the
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tests, presented here, only the four-fields multi-ion plans were studied, however, in other cases,
a reduced number of multiple-ion fields might be more beneficial.
The results of this work can be summarized as follows:
• The present status of 16O physical and radiobiological beam models allows a reliable treat-
ment plan optimization that has been confirmed experimentally;
• The knowledge of the radiobiological properties of the beam, in particular the pool of RBE
and OER values, was expanded;
• The comparative analysis of the treatment plans with 16O ions and lighter modalities re-
vealed that 16O allow the most uniform target coverage, decrease of the dose in the residual
tissue entrance channel and avoiding local hotspots in the organs at risk when the tumor
is hypoxic;
• TRiP98 TPS was upgraded to handle multiple primary beams for hypoxic tumors;
• The multiple-ion treatment planning might lead to the further improvement of the treat-
ment plan quality.
This work is expected to contribute to the transition of hypoxic tumors treatment planning
and irradiation with 16O ions into clinical routine. The recent reports and the growing number of
corresponding publications show the interest coming not from basic science, but also from the
clinicians themselves. Since several of the currently operating particle therapy centers which
offer the 12C beams possess already the possibility to irradiate with 16O beams at least for
research purpose, it is highly probable that the therapy with the latter modality can start within
the next decade.
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A X-ray response of CHO-K1 cell line
Figure A.1.: Caption.
Table A.1.: LQ parameters of the reference X-ray survival curve measured for the CHO-K1 cell
line. The numerical values of the measured points are give in Appendix E.
αX−ray (Gy−1) βX−ray (Gy−2) Dt , Gy
0.216±0.031 0.019±0.004 17
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B Water equivalent ratio of materials used
in cell irradiation setups
Material Used at WEQ Source
Cell culture medium Filling of the cell samples 1 [Grumezescu, 2016]
(rings, tissue culture flasks,
Petri dishes)
Polystyrene Tissue culture flask wall, 1.042 [de Vera et al., 2014]
range shifting material
in hypoxic phantom,
Petri dishes material
Biofolie 25 Cell growth surface of the rings 1.88 [Ma et al., 2013]
PEEK Hypoxic chamber walls 1.27 [Peter Steidl
(Polyether ether ketone) (Private communication)]
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C Calibration for beam monitors in 16O
beam at HIT facility
The procedure of the calibration of the beam monitors for heavy ion beams delivered by means
of scanning system, initially developed for the former 12C treatment facility at GSI and later
transferred to HIT, was developed and described by [Jäkel et al., 2004].
The calibration is energy-dependent and should be valid for all the available beam energies.
It is performed in units of number of particles per monitor unit. The measurement of particle
number is indirect through the measurement of absorbed dose to water with the Farmer cham-
ber. The latter has a calibration factor in terms of absorbed dose to water (60Co beam used as a
reference beam).
The chamber is placed inside the phantom consisting of water-equivalent material that is
irradiated with several (typically, five or six) fields of different fixed energies, corresponding to
different penetration depths in water. The absorbed dose is defined as follows:
Dabs = MkQNw, (C.1)
where M is the reading of the dosimeter, Nw is a calibration factor in terms of absorbed dose to
water in 60Co field, and kQ being the radiation beam quality factor accounting for the difference
between the beam of interest and the calibration beam. Based on that, the calibration factor
for a given energy E is defined as a number of particles N per monitor unit MU, assuming the
homogeneous distribution of the delivered dose:
K(E) =
N
MU
=
1
MU
Dabs∆x∆y
SE(x)
, (C.2)
where ∆x and ∆y are the raster scanner step sizes in x- and y-directions, respectively, and SE(x)
is the mass stopping power of the ions with initial energy E measured at a depth x. After that,
the calculated factors are interpolated, giving a calibration curve for the other energies.
The set of the measured calibration factors for 16O beam monitor used for a part of the
experiments presented in Chapter 2, is shown in Figure C.1. The precision of the dosimetry is
very high and, despite the small fluctuations that can be observed, the reproducibility of the
results is within less than 1%.
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Figure C.1.: Relative measured number of particles dependency on their energies measured for
the dose calibration for 16O at the experimental cave of HIT, Heideilberg in 2015.
Data are courtesy of Dr. Emanuele Scifoni.
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D Measurements of the pinpoint chambers
for the absorbed dose profiles
verification
Table D.1.: Average doses and the standard error of the mean measured by the two central
pinpoint chambers for a treatment plan optimized for a uniform RBE-weighted dose
of 4 Gy in the target.
Position, mm Dose, Gy ±SEM, Gy
61.7 2.802 0.007999
71.7 2.687 0.0015
81.7 2.523 0.007999
91.7 2.332 0.006499
101.7 2.123 0.014
111.7 1.8 0.004499
64.7 2.758 0.0009998
74.7 2.61 0.0015
84.7 2.489 0.0175
94.7 2.314 0.0004999
104.7 2.026 0.0025
114.7 0.8855 0.02885
16.7 2.159 0.006499
26.7 2.216 0.003499
36.7 2.325 0.003
46.7 2.538 0.003499
56.7 2.859 0.003
66.7 2.721 0.003999
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Table D.2.: Average doses and the standard error of the mean measured by the two central
pinpoint chambers for a treatment plan optimized for a uniform absorbed dose of 4
Gy in the target.
Position, mm Dose, Gy ±SEM, Gy
74.7 4.072 0.009998
84.7 4.03 0.0025
94.7 4.03 0.0009998
104.7 4.023 0.005999
114.7 0.6838 0.005649
124.7 0.4536 0.004649
89.7 4.038 0.013
99.7 4.006 0.005999
119.7 0.5641 0.0005499
129.7 0.379 0.004999
139.7 0.2789 0.00325
19.7 3.261 0.004999
29.7 3.349 0
39.7 3.507 0.011
49.7 3.833 0.0025
59.7 4.014 0.013
77.7 3.905 0.0025
87.7 4.131 0.012
97.7 4.089 0.018
117.7 0.6607 0.0122
127.7 0.4426 0.004649
19.7 3.227 0.008999
29.7 3.32 0.005999
39.7 3.487 0.0025
49.7 3.741 0.009998
59.7 3.952 0.0004999
69.7 4.133 0.0135
129.7 0.4148 0.003649
139.7 0.2999 0.00235
149.7 0.2385 0.0021
159.7 0.2074 0.000099
169.7 0.1741 0.004049
179.7 0.1499 0.0019
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Table D.3.: Measurements of the pinpoint chambers during the verification of the lateral dose
profile at a depth of 19.7 mm for a plan optimized for a uniform absorbed dose of 4
Gy in the target.
Distance from Dose, Measurement Distance from Dose, Measurement
the center, mm Gy error, Gy the center, mm Gy error, Gy
-82 0.0002 0.00014 -10 3.236 0.01799
-70 0.0028 0.00053 -9 3.256 0.01804
-61 0.0006 0.00024 -6 3.238 0.01799
-58 0.0011 0.00033 -3 3.229 0.01797
-50 0.0002 0.00014 -3 3.225 0.01796
-49 0.0041 0.00064 3 3.266 0.01807
-48 0.0002 0.00014 9 3.221 0.01795
-46 0.0003 0.00017 15 3.224 0.01796
-46 0.0053 0.00073 19 3.231 0.01797
-42 0.0017 0.00041 21 2.966 0.01722
-39 0.0018 0.00042 25 1.92 0.01386
-38 0.0095 0.00097 31 0.1733 0.00416
-37 0.0153 0.00124 33 0.0353 0.00188
-36 0.0124 0.00111 37 0.0128 0.00113
-34 0.0261 0.00162 43 0.0053 0.00073
-30 0.2927 0.00541 46 0.0042 0.00065
-27 0.982 0.00991 49 0.003 0.00055
-26 1.248 0.01117 55 0.0043 0.00066
-25 1.457 0.01207 57 0.0009 0.00030
-24 1.945 0.01395 58 0.0036 0.00060
-22 2.619 0.01618 61 0.0036 0.00060
-21 2.836 0.01684 69 0.0015 0.00039
-18 3.234 0.01798 70 0.0011 0.00033
-15 3.204 0.01790 81 0.0003 0.00017
-14 3.222 0.01795 82 0.0015 0.00039
-12 3.218 0.01794 93 0.0013 0.00036
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Table D.4.: Measurements of the pinpoint chambers during the verification of the lateral dose
profile at a depth of 59.7 mm for a plan optimized for a uniform absorbed dose of 4
Gy in the target.
Distance from Dose, Measurement Distance from Dose, Measurement
the center, mm Gy error, Gy the center, mm Gy error, Gy
-82 0.0002 0.00014 -9 4.001 0.02000
-70 0.0004 0.0002 -9 3.953 0.01988
-61 0.002 0.00045 -6 3.937 0.01984
-58 0.0043 0.00066 -3 3.949 0.01987
-50 0.0047 0.00069 -3 3.98 0.01994
-49 0.0042 0.00065 3 4.027 0.02007
-48 0.0106 0.00103 3 3.952 0.01988
-46 0.0106 0.00103 9 3.973 0.01993
-46 0.0104 0.00102 15 3.985 0.01996
-42 0.0148 0.00122 15 3.91 0.01977
-39 0.0187 0.00137 19 3.964 0.01991
-38 0.0197 0.00140 21 3.554 0.01885
-37 0.0275 0.00166 25 2.414 0.01554
-36 0.0303 0.00174 31 0.2515 0.00501
-34 0.0495 0.00222 33 0.0702 0.00265
-30 0.3669 0.00606 37 0.0206 0.00144
-27 1.181 0.01087 43 0.012 0.00109
-26 1.687 0.01299 46 0.0083 0.00091
-25 1.692 0.01301 49 0.0076 0.00087
-24 2.55 0.01597 55 0.0083 0.00091
-22 3.338 0.01827 57 0.0037 0.00061
-21 3.539 0.01881 58 0.0005 0.00022
-21 3.497 0.01870 61 0.0062 0.00079
-18 3.975 0.01994 69 0.0003 0.00017
-15 3.924 0.01981 70 0.0012 0.00035
-14 3.879 0.01969 81 0.0008 0.00028
-12 3.899 0.01975 82 0.0026 0.00051
-10 3.956 0.01989 93 0.0032 0.00057
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Table D.5.: Measurements of the pinpoint chambers during the verification of the lateral dose
profile at a depth of 89.7 mm for a plan optimized for a uniform absorbed dose of 4
Gy in the target.
Distance from the center, mm Dose, Gy Measurement error, Gy
-21 3.7 0.01924
-9 4.025 0.02006
-3 4.032 0.02008
0 4.04 0.02009
2 4.042 0.02010
3 4.051 0.02013
4 4.046 0.02011
6 4.031 0.02008
8 4.028 0.02007
9 4.034 0.02008
12 4.003 0.02001
14 3.995 0.01999
15 4.007 0.02002
16 3.999 0.01999
18 3.983 0.01996
19 3.974 0.01993
20 3.92 0.01979
21 3.859 0.01964
24 3.197 0.01788
26 2.416 0.01554
28 1.529 0.01236
30 0.7588 0.00871
31 0.4379 0.00662
32 0.2947 0.00543
33 0.1728 0.00416
36 0.0505 0.00225
38 0.0284 0.00169
40 0.0255 0.00159
42 0.0199 0.00141
43 0.0184 0.00136
44 0.0174 0.00132
55 0.0075 0.00087
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Table D.6.: Measurements of the pinpoint chambers during the verification of the lateral dose
profile at a depth of 129.7 mm for a plan optimized for a uniform absorbed dose of
4 Gy in the target.
Distance from the center, mm Dose, Gy Measurement error, Gy
-21 0.288 0.00537
-9 0.374 0.00612
-3 0.3844 0.00620
0 0.3866 0.00622
2 0.4018 0.00634
3 0.384 0.00619
4 0.3874 0.00622
6 0.3894 0.00624
8 0.3887 0.00623
9 0.3774 0.00614
12 0.3748 0.00612
14 0.3781 0.00615
15 0.3666 0.00605
16 0.3664 0.00605
18 0.3566 0.00597
19 0.3583 0.00599
20 0.3362 0.00579
21 0.3138 0.00560
24 0.2471 0.00497
26 0.204 0.00452
28 0.141 0.00375
30 0.0996 0.00316
31 0.0962 0.00310
32 0.0707 0.00266
33 0.0604 0.00246
36 0.0394 0.00198
38 0.0415 0.0020 4
40 0.0257 0.00160
42 0.0241 0.00155
43 0.0298 0.00173
44 0.0214 0.00146
55 0.0185 0.00136
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E Survival measurements for the data
presented in Chapter 2
Table E.1.: X-ray
Dose, Gy Survival ±SEM
0 0.9409 0.0450
1 0.8433 0.1002
2 0.6208 0.0492
4 0.3090 0.0013
6 0.1264 0.0005
8 0.0530 0.0040
Table E.2.: 16O, 3 MeV/u (670 keV/mu)
Dose, Gy Survival ±SEM
0 0.9738 0.1181
1 0.6553 0.0254
2 0.4529 0.0361
3 0.2529 0.0291
4 0.1107 0.0008
5 0.0605 0.0063
6 0.0476 0.0185
7 0.0415 0.0053
8 0.0196 0.0018
Table E.3.: 16O, 19.6 MeV/u (166 keV/mu), normoxia
Dose, Gy Survival ±SEM
0 0.9031 0.0948
0.5 0.8328 0.2088
1 0.5048 0.0486
2 0.2052 0.0301
3 0.0939 0.0030
4 0.0376 0.0068
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Table E.4.: 16O, 46.8 MeV/u (83 keV/mu)
Dose, Gy Survival ±SEM
0 1.0987 0.1037
0.5 0.7072 0.0611
1 0.4855 0.1305
2 0.2342 0.0236
3 0.1139 0.0134
4 0.0405 0.0132
Table E.5.: 16O, 146 MeV/u (38 keV/mu)
Dose, Gy Survival ±SEM
0 0.8960 0.1477
1 0.7063 0.0825
2 0.3968 0.1085
3 0.2059 0.0214
5 0.0475 0.0029
7 0.0083 0.0021
Table E.6.: 16O, 280 MeV/u (23 keV/mu)
Dose, Gy Survival ±SEM
0 0.9581 0.1423
1 0.7323 0.0005
2 0.4034 0.0559
3 0.3896 0.0052
5 0.1355 0.0124
7 0.0270 0.0022
Table E.7.: 16O, 19.6 MeV/u (166 keV/mu), anoxia
Dose, Gy Survival ±SEM
0 0.9752 0.0080
0.5 0.7428 0.0911
1 0.6878 0.0127
2 0.2820 0.0390
3 0.1930 0.0073
4 0.0923 0.0001
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Table E.8.: Extended normoxic target irradiation with 16O
Position in depth, mm Survival ±SEM
23.4 0.5191 0.0323
23.4 0.5293 0.0713
76.4 0.1147 0.0174
76.4 0.1048 0.0112
79.5 0.0838 0.0061
79.5 0.1069 0.0012
85.6 0.0993 0.0124
85.6 0.1116 0.0053
134.1 0.4950 0.0103
134.1 0.4826 0.0129
158.7 0.5574 0.0630
158.7 0.6281 0.1389
Table E.9.: Extended unevenly oxygenated target irradiation with 16O
Position in depth, mm Survival ±SEM
1.3 0.4609 0.0513
28.9 0.4464 0.0659
50.5 0.1299 0.0381
51.8 0.1331 0.0376
54.9 0.0953 0.0260
58.0 0.0884 0.0100
65.5 0.0880 0.0062
66.8 0.0895 0.0001
68.6 0.0927 0.0019
68.7 0.0809 0.0142
75.2 0.1191 0.0047
76.4 0.0929 0.0088
78.2 0.1085 0.0108
79.5 0.0944 0.0237
81.3 0.1210 0.0118
82.6 0.0982 0.0008
134.1 0.4355 0.0045
158.7 0.4772 0.0243
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F Optimization accounting for a
three-dimensional pO2 distribution
In the older version of TRiP98-OER the tissue oxygenation values could be set only in one di-
mension along the beam path, which highly restricted the applicability of the TPS, making it
useful for planning only the symmetrical fields configurations. As a part of the MoVe IT col-
laboration, the TRiP98-OER and the TRiP98-OER-multiion, updated in the frame of the current
work, was improved by adding the option of reading the external oxygenation (hypoxia) maps.
The structure of the hypoxia maps files and the procedure of its interpretation is similar to the
ones for the CT data. Including the OER effect to the optimization requires the following:
• Functional PET (e.g. FMISO) uptake data cube with the same voxel number and size as
the CT cube;
• A specific tracer (e.g. FMISO) uptake - pO2 lookup table in a way similar to the typical
Hounsfield look-up table used for CT numbers conversion. The planning tests in the current
work are done using the table based on the model approach suggested by [Bowen et al.,
2011] (Figure F.1);
• OER(pO2, LET) tables containing the base data for the OER-LET interpolation.
Figure F.1.: Visualization of the oxygenation lookup table generated according the [Bowen
et al., 2011] approach. The x -axis values correspond to the FMISO uptake signal
and the y -axis - to the recalculated pO2 values.
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Additionally, creating and loading the pO2 distribution cubes, similar to those of Hounsfield
numbers distribution cubes, is possible. This enables more realistic testing of the tool, including
the cases with real patients with hypoxic tumors.
An example of the generated ellipsoid pO2 inside a rectangular target is presented in Figure
F.2. The oxygenation is gradually decreasing from 21% until 0% towards its center.
Figure F.3 shows the example of the optimization with two opposite fields of 16O beams
using kill-painting approach for a uniform survival of 10% in the target region. The same
geometry, CT parameters and fields configuration as used in the Chapter 2 for the experiment
with extended hypoxic target was used. The result of the optimization are the uniform biological
(RBE- and OER-weighted) dose and the cell survival (Figures F.3(a), F.3(e), and F.3(d) and
F.3(h)) achieved by delivering the physical dose boost to the central target part (Figures F.3(b)
and F.3(f)). The resulting dose-averaged LET profile with a high-LET boost in the most hypoxic
part is illustrated in Figures F.3(c) and F.3(g). The corresponding results for the optimization
for the same geometry, but not accounting for the presence of hypoxia, are given in Figure F.4.
In both cases of oxygenation the dose and survival distributions look reasonable. An addi-
tional remark might be added concerning the dose-averaged LET distribution. One may notice
that the area of the relatively high values of LET extends far beyond the target borders in lateral
directions for both tests. The possible explanation to this effect can be the the presence in this
region of the few high-LET particles delivering a very low total dose.
(a) (b)
Figure F.2.: Two projections of the hypoxia map describing the emulated pO2 distribution in the
target, gradually decreasing towards its center.
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(a) (b) (c) (d)
(e) (f) (g) (h)
Figure F.3.: Plan optimized for a uniform survival of 10% in a target containing an ellipsoid hy-
poxic region in the center, irradiated with two opposite fields of 16O ions. (a), (e) -
RBE- and OER-weighted dose distribution, (b), (f) - absorbed dose distribution, (c),
(g) - dose-averaged LET distribution, (d), (h) - survival distribution. In Figures (a), (b),
(c) and (f) 100% stands for the dose of 6.5 Gy. In Figures (c) and (g) 100% stands
for the 100 keV/µm and in Figures (d) and (e) - for 100% survival. The top and the
bottom rows correspond to the coronal and axial panes.
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(a) (b) (c) (d)
(e) (f) (g) (h)
Figure F.4.: Plan optimized for an RBE-weighted dose of 6.5 Gy not accounting for the presence
of an ellipsoid hypoxic region in the center, for opposite fields of 16O ions. (a), (e)
- RBE- and OER-weighted dose distribution, (b), (f) - absorbed dose distribution, (c),
(g) - dose-averaged LET distribution, (d), (h) - survival distribution. In Figures (a), (b),
(c) and (f) 100% stands for the dose of 6.5 Gy. In Figures (c) and (g) 100% stands
for the 80 keV/µm and in Figures (d) and (e) - for 100% survival. The top and the
bottom rows correspond to the coronal and axial panes
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G Entrance channel survival data used for
analysis in Chapter 3
Table G.1.: 4 Gy, 0.5 pO2
Size, mm 12C 4He 16O
1.0 0.708 0.737 0.719
1.2 0.709 0.735 0.709
1.6 0.710 0.729 0.717
1.8 0.714 0.728 0.714
2.0 0.698 0.716 0.715
2.2 0.700 0.712 0.707
2.4 0.693 0.712 0.696
2.8 0.693 0.703 0.704
3.0 0.692 0.697 0.701
3.2 0.680 0.691 0.703
3.6 0.683 0.688 0.695
3.8 0.678 0.682 0.694
4.0 0.676 0.677 0.691
4.2 0.665 0.671 0.691
4.4 0.662 0.655 0.689
4.8 0.656 0.661 0.682
5.0 0.647 0.646 0.675
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Table G.2.: 4 Gy, 0.15 pO2
Size, mm 12C 4He 16O
1.0 0.704 0.717 0.709
1,2 0.698 0.718 0.686
1.6 0.696 0.702 0.708
1.8 0.697 0.705 0.708
2.0 0.682 0.687 0.702
2.2 0.673 0.674 0.691
2.4 0.674 0.673 0.691
2.8 0.664 0.655 0.689
3.0 0.651 0.644 0.681
3.2 0.653 0.644 0.684
3.6 0.641 0.627 0.673
3.8 0.639 0.625 0.673
4.0 0.627 0.612 0.667
4.2 0.613 0.599 0.656
4.4 0.609 0.599 0.655
4.8 0.605 0.585 0.643
5.0 0.581 0.580 0.634
Table G.3.: 6.5 Gy, 0.5 pO2
Size, mm 12C 4He 16O
1.0 0.527 0.567 0.529
1.2 0.516 0.567 0.512
1.6 0.518 0.559 0.524
1.8 0.524 0.557 0.522
2.0 0.504 0.539 0.522
2.2 0.502 0.533 0.512
2.4 0.491 0.534 0.495
2.8 0.497 0.524 0.506
3.0 0.486 0.512 0.506
3.2 0.481 0.502 0.505
3.6 0.477 0.500 0.492
3.8 0.474 0.496 0.492
4.0 0.468 0.485 0.492
4.2 0.452 0.477 0.487
4.4 0.448 0.460 0.484
4.8 0.439 0.462 0.473
5.0 0.427 0.443 0.464
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Table G.4.: 6.5 Gy, 0.15 pO2
Size, mm 12C 4He 16O
1.0 0.509 0.543 0.513
1.2 0.504 0.541 0.494
1.6 0.498 0.527 0.512
1.8 0.501 0.519 0.512
2.0 0.478 0.502 0.502
2.2 0.467 0.476 0.487
2.4 0.471 0.478 0.489
2.8 0.454 0.454 0.484
3.0 0.435 0.439 0.473
3.2 0.435 0.438 0.478
3.6 0.420 0.416 0.460
3.8 0.408 0.414 0.462
4.0 0.403 0.400 0.452
4.2 0.377 0.387 0.438
4.4 0.376 0.391 0.436
4.8 0.371 0.370 0.419
5.0 0.355 0.360 0.408
Table G.5.: 7.5 Gy, 0.15 pO2
Size, mm 12C 4He 16O
1.0 0.457 0.505 0.457
1.2 0.444 0.503 0.438
1.6 0.446 0.495 0.450
1.8 0.453 0.494 0.449
2.0 0.430 0.476 0.450
2.2 0.428 0.469 0.426
2.4 0.417 0.470 0.417
2.8 0.424 0.459 0.433
3.0 0.404 0.448 0.433
3.2 0.406 0.433 0.431
3.6 0.402 0.432 0.418
3.8 0.402 0.432 0.421
4.0 0.393 0.417 0.417
4.2 0.370 0.409 0.412
4.4 0.372 0.395 0.408
4.8 0.362 0.392 0.398
5.0 0.350 0.373 0.390
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Table G.6.: 7.5 Gy, 0.15 pO2
Size, mm 12C 4He 16O
1.0 0.434 0.479 0.440
1.2 0.429 0.484 0.428
1.6 0.423 0.466 0.438
1.8 0.427 0.464 0.438
2.0 0.404 0.441 0.428
2.2 0.390 0.427 0.412
2.4 0.395 0.432 0.412
2.8 0.384 0.406 0.410
3.0 0.355 0.396 0.398
3.2 0.360 0.394 0.402
3.6 0.342 0.377 0.383
3.8 0.348 0.376 0.385
4.0 0.326 0.357 0.374
4.2 0.304 0.351 0.360
4.4 0.304 0.350 0.358
4.8 0.293 0.330 0.340
5.0 0.277 0.320 0.330
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